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More than 150 experts from science, policy and business discussed new strategies  
and future perspectives of Blue Biotechnology in the Baltic Sea Region.
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The Panelists: Jan-Bart Calewaert (Marine 
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Institute) Fernando de la Calle (Phar-
maMar), Torger Børresen (DTU Food)
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Foreword
Blue Biotechnology has the potential to offer answers to global challenges related to 
human health, food demands, and environmental concerns. It is still a young discipline 
that currently develops its contours. But the global market for products, technology 
and services based on marine resources continuously increases – a fact that requires 
effective networking and adopting a solid position to persist within this very dynamic 
surrounding.
The Marine Board of the European Science Foundation (ESF) rates the global market in 
this segment to be 2.8 billion €, with annual growth rates of 12 %. A background report 
of the EU’s Blue Growth initiative predicts the Baltic Sea Region to play a major role in 
Blue Biotechnology in the future.
SUBMARINER is for the first time comprehensively assessing the economic feasibility, 
the regional applicability and the environmental impacts of a number of new marine 
uses in the Baltic Sea Region. With a view to its enormous development potential, we 
selected Blue Biotechnology as one of the topics for this assessment. The perspectives 
assembled in this publication are thus an important input to the policy recommenda-
tions for furthering beneficial marine uses that we are developing within the project. 
They are based on the presentations held at the SUBMARINER Blue Biotechnology in 
Kiel, Germany in May 2012.
Kiel was the obvious place to host this Cooperation Event as some of the Baltic Sea 
Region’s key research institutions are located there. What is more, Schleswig-Holstein 
is currently developing a comprehensive regional development strategy for Blue Bio-
technology as part of the SUBMARINER project.
SUBMARINER hosted a Blue Biotechnology Cooperation Event 
in Kiel, Germany on 9 and 10 May 2012.
Joanna Przedrzymirska
The Maritime Institute in Gdańsk
SUBMARINER Lead Partner
After an algae conference in September 2011, the Blue Biotechnology conference was 
the second in a series of SUBMARINER Cooperation Events. In collaboration with the 
Aquabest project, SUBMARINER is now co-organising the Åland Aquaculture Week to 
be held in October 2012. This event will provide the opportunity to discuss ways to-
wards a sustainable fish aquaculture and the potential of mussel farming in the Baltic 
Sea Region.
Key messages for the Baltic Sea Region
Can the Baltic Sea Region be a model region for Blue Biotechnology? And which steps 
have to be taken to strengthen the region’s competitiveness in this field? These were 
the leading questions of the Cooperation Event’s concluding panel discussion. These 
are some of the recommendations that the panelists came up with:
 → Develop national Blue Biotechnology strategies in cooperation with other Baltic 
Sea Region states and aligned with the EU level,
 → Formulate clear ambitions for the Baltic Sea Region in the field of Blue Biotech-
nology and focus on strengths and market needs,
 → Make sure that Blue Biotechnology is “truly blue” and sustainable, i.e. to the ben-
efit of the sea,
 → Improve the modalities of technology transfer to achieve better exploitation of 
scientific results and patents, 
 → Make better use of existing support technologies and platforms and strengthen 
application-oriented approaches
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State-of-the-Art and Future Perspectives 
of Blue Biotechnology
At the European level, Blue Biotechnology is seen as an important contribution 
to addressing grand challenges of the 21st century and to fulfilling the Europe 
2020 strategy. Jan-Bart Calewaert from the Marine Board of the European Sci-
ence Foundation presents some of the key policy documents on the European 
level, such as the Copenhagen Declaration for a Bioeconomy in Action and the 
Marine Board’s Position Paper on Marine Biotechnology. 
On the Baltic Sea Region level, an overarching strategy for Blue Biotechnology 
does not yet exist. In her contribution, Jutta Wiese (GEOMAR | Helmholtz Centre 
for Ocean Research Kiel) shows that such a Baltic Sea Region strategy is needed 
to realise the visions and recommendations that the SUBMARINER project has 
developed based on its assessment of the state-of-the-art of Blue Biotechnology 
around the Baltic Sea.
Denmark is currently the only Baltic Sea Region country that has a national Blue 
Biotech strategy in place. In his article, Torger Børresen (DTU Food) describes the 
six priorities of the Danish government’s 2010 report on the development of 
marine biotechnology in Denmark.
In Germany, a regional Masterplan Marine Biotechnology for the state Schleswig-
Holstein is being developed as part of the “Sea our Future” initiative within the 
SUBMARINER project. Focusing on the Kiel Centre for Marine Natural Products, 
Johannes F. Imhoff (GEOMAR | Helmholtz Centre for Ocean Research Kiel) intro-
duces the Northern German research institutions active in the field. 
The key drivers for furthering Blue Biotechnology in the Baltic Sea Region are its 
strong research institutions. Ongoing Blue Biotech projects from Finland and Po-
land are presented by Alicja Kosakowska and Adam Żak (Institute of Oceanology, 
Polish Academy of Sciences) as well as Päivi Tammela (University of Helsinki).
A showcase from Lithuania demonstrates how Blue Biotechnology can be turned 
into profitable business: Vytas Rimkus presents the microalgae applications for 
human food, health and animal feed that his company SPILA is involved in.
The interest of the scientific community, and to a lesser extent 
of industry, in marine biotechnology has grown rapidly in the 
past decade owing to a recognition of the sheer scale of oppor-
tunity presented by the largely unexplored and unexploited bio-
diversity of our seas and oceans and the need to meet growing 
demands that cannot be satisfied from terrestrial sources alone. 
Several publications (e.g. from Marine Board-ESF, European 
Commission CWG and EU-US Task Force on Biotechnology) have 
highlighted the importance of marine biotechnology and its po-
tential to make a significant contribution to sustainable develop-
ment on all fronts, including social, economic and environmen-
tal. However, it is only since recently that a concerted effort is 
being made in Europe to develop an initiative that seeks to take 
action on many of the issues identified, to improve the coordi-
nation of marine biotechnology research, raise its profile, and 
contribute to the establishment of the Knowledge Based BioEc-
onomy (KBBE).
This presentation sketched key policy developments of Euro-
pean marine biotechnology in the last decade, highlighted areas 
of progress and addressed future perspectives. It presented 
some of the main opportunities and challenges identified by 
strategic exercises and assessed where we are in realising the 
vision and strategy for Europe proposed in Marine Board Posi-
tion Paper 15 on Marine Biotechnology. Finally, the presentation 
highlighted some of the outcomes of the FP7 CSA MARINEBIO-
TECH project (www.marinebiotech.eu), in particular the pre-
liminary results of the mapping of European Marine Biotechnol-
ogy Research landscape being conducted by Marine Board-ESF.
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Overview of recommendations from the Marine Board-ESF’s position paper on Marine Biotechnology
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The SUBMARINER project seeks to turn the Baltic Sea into a 
model region by fostering sustainable economic development 
and improved environmental conditions through new maritime 
products and technologies. In this project the Kieler Wirkstoff-
Zentrum (Centre of Marine Natural Products) at GEOMAR fo-
cuses on aspects of Blue Biotechnology.1  It is responsible for the 
chapter on Blue Biotechnology in the SUBMARINER Compendi-
um, a comprehensive inventory of innovative uses of Baltic ma-
rine resources.
According to the Internal Co-ordination Group for Biotechnolo-
gy (ICGB) Blue Biotechnology has a considerable potential to ad-
dress global challenges in population health, food security, in-
dustry and environmental sustainability as well as protecting 
and preserving marine resources for future generations.2 The 
exploration of marine microorgansims (bacteria, fungi, microal-
gae) and macroorganisms, such as algae or mussels, which are 
largely untapped, is a promising tool to find solutions for these 
challenges. 
Examples for solutions provided by Blue Biotechnology are:
 · Strong need for the discovery of therapeutic agents: 
providing new drugs for the treatment of metabolic diseas-
es (diabetes), inflammatory diseases, neurological diseases 
(dementia), cardiovascular diseases (stroke), and diseases 
caused by antibiotic resistant pathogens, etc. 
 · Strong need for new products with environmental friend-
ly properties in comparison to known products: providing 
new compounds used in plant protection, new feed for the 
cultivation of marine organisms in aquaculture, new prod-
ucts for the treatment of diseases of marine organisms, new 
anti-fouling paints, etc. 
state-of-the-art and future Perspectives | BaLTiC sea region
Blue Biotechnology all around the Baltic Sea
Jutta Wiese | GEOMAR | Helmholtz Centre for Ocean Research Kiel, Germany
 · Strong need for new technologies to be used in the im-
provement of the environmental conditions: providing 
new products for the reduction of nutrients in marine hab-
itats, bioremedation, environmental monitoring, etc.
Furthermore, Blue Biotechnology provides a huge economic 
value. According to the Marine Board of the European Science 
Foundation (ESF) the market in this segment is rated to be 
2.8  billion € with an annual growth potential of 12 % assuming a 
cooperation of industry and science.3
Assessing Blue Biotechnology in the Baltic Sea Region
The SUBMARINER Compendium aims at assessing the state-of-
the-art and perspectives of Blue Biotechnology of all countries 
around the Baltic Sea, to evaluate further applications and to 
define technical requirements taking into account environmen-
tal aspects, legal regulations and economic aspects. This assess-
ment will characterise the future potential of marine resources 
for Blue Biotechnology and will work out major obstacles to the 
further development of this field. 
Promising scientific approaches and case studies of companies 
working in the discovery and/or economical exploitation of re-
sources from the Baltic Sea are present in all countries, which 
are covered by the study, i.e. Denmark, Estonia, Finland, Ger-
many, Latvia, Lithuania, Poland, and Sweden. Among these re-
sources are raw materials, valuable ingredients such as bioac-
tive compounds, fatty acids, enzymes, biopolymers as well as 
genetic resources for biotechnological applications in pharma-
ceutical industry, medical products, human diet, animal feed, 
cosmetic, wellness sector, bioremediation and others (Figure 1). 
Raw materials 
Biomaterials 
Gene pools
Valuable ingredients (bioactive 
compounds, pigments, fatty acids, 
enzymes, antioxidants)…
Marine pharmaceutical pipeline 
Medical devices 
Marine animal health 
Cosmetics / Health care / Wellness 
Nutraceuticals / Food
Feed for aquaculture 
Bioremediation 
Bioenergy 
Anti-fouling paints 
Marine technologies…
Applications
Resources
Figure 1: 
Biodiversity of microor-
ganisms (bacteria, fungi, 
microalgae) and 
macroorganisms (e.g. 
sponges, mussels, 
macrooalgae) from the 
Baltic Sea as source of 
high-value products 
providing benefits for 
science & industry, for 
human health & environ-
ment as well as for 
growth & economy of 
the Baltic Sea Region.
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All activities in this field aim to enhance the awareness in the 
public and in the scientific community, to improve human and 
environmental health as well as to increase economic benefits.
The potential of Blue Biotechnology of providing benefits for 
academia, companies, society and policy has been recognized 
and becomes visible by the following examples:  
 · Europe: Report “Blue Growth - Scenarios and drivers for 
Sustainable Growth from the Oceans, Seas and Coasts” on 
behalf of the DG Mare of the European Commission (2012)4
 · Denmark: Report „The Ocean – an unexploited resource“ 
by the Ministry of Food, Agriculture and Fisheries Denmark 
(2010)
 · Estonia: Report on „Estonian biotechnological programme, 
a feasibility study“ (2010)
 · Finland: EU project MAREX (2010–2014)
 · Germany: Initiative “Zukunft Meer - Sea our Future” by the 
Ministry of Science, Economic affairs and Transport 
Schleswig-Holstein (2005); “Kieler Wirkstoff-Zentrum”; 
“Masterplan Marine Biotechnology Schleswig-Holstein” (in 
progress); EU projects Marine Fungi and MicroB3
 · Latvia: Establishment of the Latvian Biotechnology Associa-
tion (2006)
 · Lithuania: Studies on microalgae – diversity and potential 
for biotechnology (in progress)
 · Poland: EU project MAREX (2010–2014)
 · Sweden: INTERREG IV A project Blue Biotechnology for sus-
tainable innovations in the region Öresund-Kattegat-Sk-
agerrak (cooperation with Norway, 2011–2013)
The first results from the SWOT (Strengths, Weakness, Oppor-
tunities, Threats) analysis carried out for the SUBMARINER Com-
pendium clearly demonstrate the high potential of Blue Biotech-
nology for the Baltic Sea Region. Especially the development of 
a strategy for the implementation of promising fields of Blue 
Biotechnology in the Baltic Sea Region would help in the realisa-
tion of visions such as:
 · Establishment of a Baltic Sea Region Blue Biotech Network
 · Establishment of a “Centre for Bioprospecting Baltic Sea 
Microorganisms” 
 · Distribution networks for cosmetics/health care/wellness 
products from the BSR
 · Development of new drugs from the BSR
 · Marine genomics as source of novel enzymes from the BSR
 · Novel feed from the BSR for marine aquaculture 
 · Innovative marine technologies from the BSR
 · Innovative anti-fouling products from the BSR
Blue Biotechnology provides great potential for the Baltic Sea 
Region. However, a close cooperation between academia, in-
vestment and commercial organisations as well as policy is es-
sential to successfully transfer the findings from ecological in-
vestigation to biotechnological application and marketing. 
The ultimate hope of our activities in the framework of SUBMA-
RINER is to strengthen the Baltic Sea Region´s competitiveness 
in Blue Biotechnology and to contribute to a sustainable devel-
opment of the Baltic Sea Region. 
On all shores of the 
Baltic Sea, the 
potential of Blue 
Biotechnology has 
been recognized.
References
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Denmark is surrounded by water and has a long tradition for 
marine and maritime activities, including exploitation of aquatic 
resources. The development of marine biotechnology for fur-
ther improvement in aquaculture and other utilisation of re-
sources from the aquatic environment is thus of high interest for 
new commercial operations. Many companies are already major 
players within areas such as enzyme production, fine chemicals 
and food additives, pharmaceuticals and ship paints, all with rel-
evance and connection to the aquatic environment.
A survey initiated by the Ministry of Food, Agriculture and Fish-
eries and published in 2010 resulted in six priorities for the de-
velopment of marine biotechnology in Denmark. Business op-
portunities were suggested and some elements for a successful 
strategy were proposed. 
state-of-the-art and future Perspectives | DenMark
Six priorities proposed for marine biotechnology in Denmark
Torger Børresen | DTU Food, Denmark
Increased exploitation of marine biomass
In addition to traditional fisheries, full utilisation of all catches 
and improved utilisation of by-products are suggested. Further, 
new species of fish and macro algae should be harvested. The 
further development of this area should be seen in the perspec-
tives of the biobased society, where all components in a given 
raw material are being utilised. The Strategic Research Council 
has suggested an increased effort to develop new energy re-
sources through biorefineries in order to release the sources of 
bioenergy. Both micro and macro algae are potential raw mate-
rials for pursing the new goals.
New farming operations
Aquaculture should be applied in its widest sense. Marine farm-
ing has the advantage that it does not impact freshwater re-
sources. If established on land, water should be re-circulated 
and production limited to high priced species. Finfish species 
not farmed yet should be brought into production if obtaining 
satisfying prices on the market. For all stages of life cycle devel-
opment and for controlling diseases principles of molecular aq-
uaculture should be applied, implementing use of omics tech-
nologies and other techniques of molecular biology. Optimal 
development of farming the oceans is seen by introducing Inte-
grated Multi Throphic Aquaculture (IMTA), in which species at 
different throphic levels interact with each other in order to 
minimise the effects on the surrounding environment.
Healthy diet
Marine fatty acids, proteins, peptides and micronutrients are 
found in large quantities in marine organisms and should be 
contained directly or indirectly in the human diet. It is well es-
tablished that omega-3 fatty acids are valuable nutritional com-
ponents necessary for preventing heart diseases and for devel-
opment of the brain, but the same fatty acids are also believed 
to have a number of other health effects like preventing osteo-
porosis and improving joint functions and central metabolic 
pathways. Further many new effects have been discovered for 
marine proteins and peptides resulting from hydrolysis of frac-
tions considered as waste. Among the effects are antioxidant 
and anti cancer effects are seen such as angiotensin converting 
enzyme (ACE) inhibition. Some of the effects are thought to be 
potentiated if the lipids, proteins or peptides are acting togeth-
er with non-protein nitrogenous compounds, such as taurine, 
occurring e.g. in high amounts in the fish gut fraction.
Discovery of new compounds,  
materials and biological activities
The large variation of marine organisms and the occurrence un-
der extreme living conditions increase the chances for new com-
mercial viable discoveries. Many studies within marine biology 
are being characterised as biodiscoveries, showing potential ap-
Cover page of the Danish government’s report 
on possibilities of Blue Biotechnology and the 
use of marine resources
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Denmark is surrounded by water and has a 
long tradition for marine and maritime 
activities. The development of marine 
biotechnology is thus of high interest for 
new commercial operations.
plications of new biological principles through bioprospecting, 
in which commercial potentials can be developed. Many marine 
environments have shown habitats for life forms under extreme 
conditions of high or low temperature, high pressure and com-
position of minerals and nutrients being far from satisfying for 
terrestrial organisms. Many new biological principles, enzymes 
and components have already been discovered, but it is be-
lieved that we have seen only the beginning of this development 
until now. The Danish oceanic expedition around the world, 
Galathea 3, sampled water and sediments on an eight months 
cruise covering both arctic and Antarctic waters in 2006–2007.
Extraction of valuable biochemical components
Complex structures with special properties can be included in 
pharmaceutical products, cosmetics and special foods. The in-
vertebrates of the oceans are a rich source of new components 
and in many cases can lead us to a better understanding of life 
forms in organisms like e.g. sponges. The sea urchin group con-
tains such a large variation of species that some can be used for 
foods while others are toxic, and others still, contain complex 
components that already have been used for medical purposes. 
As these components are studied in further details new applica-
tions within the pharmaceutical area are considered, and exam-
ples have been found of anticancer effects and components 
being used for treatment of e.g. malaria. In many cases the 
structures are so complex they cannot be made by chemical syn-
thesis, and it may be difficult to transfer genes for production in 
other organisms.
Biofilm – from ships over the food industry to the 
interior of the human body
Biofilm is a deposit and growth of organisms on surfaces, usu-
ally with consequences unwanted for economical or health rea-
sons. The mechanism for building biofilms on surfaces are quite 
well known, but possibilities for preventing formation of bio-
films are largely unknown. Obvious areas where such prevention 
is wanted are e.g. ship paints and surfaces in the industry, where 
cleaning of surfaces in the food processing industry presents 
many problems. A new, more controversial area is bacterial film 
formation inside human blood vessels observed in certain dis-
eases.
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Through close co-operation within the EU FP7 project MAREX 19 
industrial and academic partners from 13 countries are explor-
ing marine resources for novel bioactive compounds by collect-
ing, isolating and classifying marine organisms from the Atlantic, 
Pacific and Indian Oceans as well as from the Mediterranean, 
Baltic and Arabian Seas. The main objectives of MAREX are to 
isolate, characterise, and sustainably exploit new compounds 
from extracts prepared from marine organisms that have been 
harvested from the seas and oceans, culture collections, or ac-
quired from institutional, local, national, and commercially avail-
able collections. The extracts are subjected to a highly repre-
sentative and diverse panel of multidimensional bioactivity as-
says and most promising extracts showing bioactivities will be 
subjected to chromatographic separation. Isolated marine com-
pounds are characterized thoroughly in terms of analytical pu-
rity and chemical structure. The most interesting hits will be 
produced via sustainable biotechnological processes or struc-
turally optimized in a sustainable medicinal chemistry pro-
gramme with the aim of developing therapeutic agents to the 
stage where they are available for thorough early-ADME and 
toxicological evaluation. Furthermore, the extracts prepared 
from marine organisms as well as isolated fractions and pure 
compounds will be screened and tested for other industrially 
interesting applications, such as nutraceuticals, cosmetics, agro-
chemicals and other speciality chemicals (e.g. antibiofilm agents, 
antifoulants). One of the objectives is also to develop biosensors 
for monitoring the quality of marine organism-based food and 
the biotechnological production of targeted bioactive com-
pound for process control purposes.
state-of-the-art and future Perspectives | LaTVia
MAREX: Exploring marine resources for bioactive compounds – 
From discovery to sustainable production and industrial applications
Päivi Tammela, Paula Kiuru, Tiina Lipiäinen, Jari Yli-Kauhaluoma & Heikki Vuorela |  
Phaculty of Pharmacy, University of Helsinki, Finland
During the first 18 months of the project, a vast number of ma-
rine organisms, such as micro- and macroalgae, dinoflagellates, 
sponges, sea anemones, sea cucumbers and cyanobacteria from 
European, Asian and South American marine and brackish eco-
systems have been collected and extracted. The crude extracts 
of marine organisms have been processed to isolate and chemi-
cally characterize their most potent bioactive compounds by 
chromatographic separation and structure identification. The 
main results are (i) isolation and characterization of cytostatic 
and apoptotic polyether triterpenoids from red seaweed Lau-
rencia viridis, (ii) discovery of serine protease and protein phos-
phatase inhibiting oligopeptides from the Baltic cyanobacterium 
Nodularia spumigena, and (iii) discovery of theonellasterol as a 
potent and selective bile acid receptor antagonist.
Extracts, fractions and isolated or synthesized compounds pro-
duced during the project are being comprehensively studied for 
their potential use in pharmaceutical, cosmetic, food/nutraceu-
tical, agricultural and other applications in more than 50 differ-
ent biological activity assays. The key discoveries are: (i) several 
antiproliferative and pro-apoptotic hits have been identified, (ii) 
many samples have been identified as inhibitors or antagonists 
of thrombin, trypsin, fibrinogen receptor or vitronectin recep-
tor, (iii) extracts with anti-inflammatory effects have been iden-
tified, (iv) synthetic derivatives interacting with sodium channels 
have been discovered, (v) antifungal and antibacterial screening 
have revealed many active samples against e.g. Candida albi-
cans, Staphylococcus aureus and Cryptococcus neoformans, (vi) 
protein phosphatase assays have shown stimulating effects by 
marine organism -derived compounds.
The MAREX consortium:
• University of Helsinki – Finland (Coordinator)
• University of Ljubljana – Slovenia
• University of La Laguna – Spain
• University of Gdansk – Poland
• Katholieke Universiteit Leuven, Belgium
• Åbo Akademi University – Finland
• American University of Beirut – Lebanon
• Universidad de Antofagasta – Chile
• University of Strasbourg – France
• Ege University – Turkey
• Università Degli Studi di Napoli ‘Federico II’ – Italy
• Universidad Catolica del Norte – Chile
• Technical Research Centre of Finland (VTT) – Finland
• National Institute of Oceanography – India
• Acreo AB – Sweden
• Xention – United Kingdom
• BioVivo – Poland
• Ebiotec S.A. – Spain
• BiotechMarine – France
The Latvian Biotechnology association (LBA) was created as the 
first Latvian biotech network in 2006. 
The main aim of the LBA is to promote the development of bio-
technology in Latvia by clustering of academia, governmental 
bodies and industry in joint projects, by participation in the in-
ternational projects, by joint representation of their members 
in meetings and exhibitions, by promoting of education of young 
specialist in biotechnology and related fields, and by rising of 
public awareness on biotechnology in the society. LBA is a mem-
ber of European Federation of Biotechnology and ScanBalt net-
work.
The activities of Latvian Biotech SME, which use biotechnologi-
cal methods in manufacturing and service, are oriented to the 
following directions:
1. The medical and pharmaceutical biotechnology;
2. The ecological biotechnological;
3. The design and manufacturing of the biotechnological 
equipments;
4.  The Industrial biotechnology.
The biggest turnover is in the direction of the biotechnological 
equipments (different laboratory equipment, as well laboratory 
and pilot scale bioreactors), although the amount of companies 
Trends of biotechnology in Latvia
Juris Vanags | Latvian Biotechnology Association, Latvia
are relatively small, they have the international recognition. 
Now research institutions and companies consider the opportu-
nities to start activities in directions of blue biotechnology. As 
the first steps is the adaptation of methods used by potential 
partners of EU countries. 
Potential of Latvian biotechnology
The potential of the Latvian biotechnology is in the availability 
of the corresponding specialists and students. Regardless of the 
fact, that the conditions for the more rapid development of the 
biotechnology are being created insufficiently intensive, which 
is mainly connected with the poor availability of the invest-
ments, because the local investors are oriented towards the 
more rapid profit bringing branches, however the foreign inves-
tors have taken the wait-and-see position.
In order to promote the more rapid development of the Latvian 
biotechnology, the scientific researches are to be focused in the 
most topical directions, it is necessary to promote the SME ac-
tivities, as well as the international collaboration has to be de-
veloped in the sphere of the initiation of the larger projects, as 
well as it is necessary to solve the issues, connected with the 
investment attraction. 
The potential of the 
Latvian biotech-
nology lies in the 
availability of the 
corresponding 
specialists and 
students.
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The MAREX project has also studied biotechnological produc-
tion of marine organisms and biosensing. The highlights of these 
studies are: (i) a successful optimization of the dinoflagellate 
Prorocentrum lima cultivation, (ii) evaluation of several bioreac-
tor types for production of microalgae biomass; (iii) establish-
ment of cryopreservation strategies for microalgal species; (iv) 
promising results from an aptamer selection against marine 
toxin okadaic acid; and (v) the development of a biomolecular 
detection assay and digital microfluidics.
In addition, design and synthesis of derivatives and analogs of 
marine bioactive compounds, their structure-activity relation-
ships analyses, and development of the most promising hits to 
lead compounds have been carried out. The major results in-
clude (i) the first total syntheses of marine sulfated sterols solo-
monsterols A and B, (ii) compound libraries of marine com-
pound- based derivatives have been designed and synthesized 
for bioactivity assays, and (iii) homology models of human volt-
age-gated sodium channels 1.3 and 1.4 have been built.
Research carried out so far within the MAREX project has dem-
onstrated the potential of marine environment for offering lead 
compounds for pharmaceutical, nutraceutical, cosmetic, agro-
chemical, food processing, material and biosensor applications. 
Biodiversity in the seas is far from being fully explored. Classifi-
cation of marine organisms exceeds 230,000 species; in the Eu-
ropean seas over 36,000 species are known and 5,000–20,000 
species are estimated to be still undiscovered. The maritime ter-
ritory of the European Union is the world’s largest with an eco-
nomic zone covering 25 million km². The Atlantic Ocean, the 
Mediterranean Sea, the Aegean Sea, the Tyrrhenian Sea, the 
Adriatic Sea, and the brackish Baltic Sea can be regarded as the 
most important ones for the EU. Despite the values of marine 
organisms, many species have become threatened by human 
activities. Therefore, some of the core activities in MAREX, such 
as developing sustainable industrial processes based on biotech-
nological production and synthetic chemistry, are highly impor-
tant for environmentally conscious exploration of the marine 
environment for human benefit. 
The research leading to these results has received funding from 
the European Union Seventh Framework Programme [FP7/2007–
2013] under grant agreement n° 245137.
www.marex.fi
Finland is coordinating the large-scale  
FP7 project MAREX – Exploring Marine 
Resources for Bioactive Compounds.
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The marine environment has great potential for providing us 
with food, industrial raw materials and energy, but this potential 
remains largely unused.
In the light of this situation and taking into account today’s cli-
mate change problems in the marine environment, especially 
the decline of phytoplankton over the past century, the Univer-
sity of Gothenburg in Sweden (lead partner) has in collaboration 
with (among others) Mare Life in Norway developed a cross-
border project in order to establish a strong research and in-
novation area for blue (marine) biotechnology in the Kattegat-
Skagerrak region. The project, called ‘Blue biotechnology for 
sustainable innovations’, focuses on commercialization of re-
search, enterprise integration and micro algae.
“Blue Biotechnology for sustainable innovations” is a project 
part-financed by the Interreg IVA-program (Kattegat-Skagerrak 
sub-program) of the European Union. The project runs over a 
three-year period, from January 2011 to December 2013.
Blue Biotechnology for sustainable innovations –  
a Blue Biotech project in the Kattegat and Skagerrak
The vision of the project is that the region around Skagerrak and 
Kattegat in ten years will be one of the most dynamic research 
and innovation locations for blue biotechnology. The region will 
have attracted internationally renowned scientists and the na-
tional and international research funding will have increased by 
a factor of 20. Furthermore, open innovation and other charac-
teristics of the chosen strategy will have led to a prosperous 
industrial centre for blue biotechnology.
To help to achieve this, the project will for example establish 
strong academic-industrial networks and collaborations; create 
an attractive research environment in the ‘KASK region’; en-
hance the knowledge of the climate effects on phytoplankton 
and try to find new sustainable ways of exploiting the resources 
that the oceans offer.- A created network between schools, 
companies, competence centers and universities.
www.bluebio.org
Maritime Strategy 
for Västra Götaland
The Maritime Strategy for the Swedish region Västra Götaland (2008) stresses the need for more expanded 
research in the field of marine biotechnology in order to meet its objective of preserving marine biodiversity 
and the marine ecosystems’ status. 
In 2011, a regional maritime cluster initiative was launched, involving a wide range of ecosystem goods and 
services from shipping to marine biotechnology (right).
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Blue Biotechnology in Germany – the Kiel Centre  
for Marine Natural Products KiWiZ
Johannes F. Imhoff | GEOMAR | Helmholtz Centre for Ocean Research Kiel, Germany
The local study “Sea our Future” in the state Schleswig-Holstein 
in 2004 and the ESF Marine Board Position Paper No. 15 on “Ma-
rine Biotechnology: A New Vision and Strategy” in 2010 both 
highlight the extraordinary importance of development of Blue 
Biotechnology in the local and the European context.
In contrast to a number of other European countries Germany 
currently lacks national efforts on a marine biotechnology ini-
tiative. In Germany research and development activities in ma-
rine biotechnology are scattered and studies on marine natural 
products lack a powerful institution to promote this topic. On 
the regional level, blue biotechnology has been recognised as an 
important field in Schleswig-Holstein and is part of activities for-
mulated in a strategic “Masterplan Marine Biotechnology 
Schleswig-Holstein”. Research on marine biotechnology and/or 
marine natural products is a major and strategic part of just a 
few German institutions:
The Fraunhofer Research Institution for Marine Biotechnology 
in Lübeck has put its focus on isolation and utilisation of stem 
cells of fish and on integrative aquaculture, but does not include 
other topics of marine biotechnology and does not work on ma-
rine natural products.
The Institute for Marine Resources GmbH imare in Bremer-
haven has its focus on biosensor technology, technical applica-
tions of marine structures and nanomaterials, but does not per-
form marine natural products research. It was established in 
2009 and is supported by finances through EFRE and from the 
state Bremen.
The Institute of Marine Resources e.V. IMaB in Greifswald ex-
ists since 1996 and operates with participation of members of 
the university Greifswald. It is build as a virtual institution or-
ganised in projects. Scientific activities include functional 
genomics, expression systems, natural products and marine en-
zymes.
The Kiel Centre for Marine Natural Product Research KiWiZ is 
embedded in the Helmholtz Centre for Ocean Research GEO-
MAR and represents a minor activity of this centre. It was estab-
lished in 2005 and supported through EFRE and the State 
Schleswig-Holstein finances until 2011 and is now an exclusive 
activity of the Research Unit Marine Microbiology of GEOMAR. 
It is specifically focused on marine natural products from marine 
bacteria and fungi and represents a major research facility of 
marine biotechnology in Northern Germany.
KiWiZ’ mission and aims
The Kiel Centre for Marine Natural Products KiWiZ is a platform 
for natural product research from marine microorganisms cov-
ering aspects from the habitat to the hit for drug candidates and 
for other uses. KiWiZ aims to include research on ecological as-
pects of natural products as well as the sustainable biotechno-
logical production of compounds valuable for various applica-
tions such as human and veterinary medicine, cosmetic, food or 
feed. It essentially works on the biology and chemistry of ma-
rine natural products.
The focus of the KiWiZ at GEOMAR is on identification, produc-
tion and promotion of new natural products from marine sourc-
es and the investigation of their biological activities and eco-
logical function. The KiWiZ was founded as an initiative of the 
state Schleswig-Holstein in northern Germany with the aim to 
establish a research platform for exploration of marine micro-
bial resources and to search for natural products and study their 
biotechnical production for various applications.
The KiWiZ is incorporated into the Helmholtz Centre for Ocean 
Research GEOMAR (formerly the Leibniz-Institute of Marine Sci-
ences) in Kiel. 
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Figure 1: Strategic outline of the research profile of KiWiZ 
for a sustainable discovery and development of marine 
microbial natural products (Imhoff et al., 2011, Biotech. 
Adv. 29:468–482).
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Research Strategy of KiWiZ
With its unique setup and resources, the KiWiZ has developed 
into an excellent scientific centre on new natural products from 
marine microorganisms. KiWiZ is operated by an interdiscipli-
nary team of microbiologists, chemists, geneticists, pharmacists 
and biotechnologists. Basic and applied research represents the 
full value chain from the marine habitat to the biotechnology 
product. It is a research platform for continuous supply of new 
natural products from marine resources in early drug discovery. 
With its expertise in marine drug discovery KiWiZ represents a 
significant aspect of the blue biotechnology in Schleswig-Hol-
stein, Germany and Europe. 
The research of KiWiZ relies on the very high diversity of marine 
microorganisms either newly cultured with special intention or 
contained in the large culture collections of marine bacteria and 
fungi strains covering more than 15,000 isolates, with a high 
proportion of new and unknown taxa. Important aspects be-
came the growing panel of biological assay systems, in which 
suitability for specific applications is tested and the establish-
ment of a substance library of pure marine natural products. 
Major results are patented with priority and then published in 
order to safe intellectual property rights for possible industrial 
application. Studies of the KiWiZ include all aspects from sam-
pling, isolation and identification of the microorganisms, their 
preservation in culture collections, the extraction, purification, 
structure elucidation and characterization of natural products 
from the cultured bacteria and fungi, optimisation of production 
conditions and scale up to a pilot scale for biotechnological pro-
duction of bioactive natural products (Fig. 1). 
Research Topics of KiWiZ
Research on bioactive compounds has two major aspects. The 
first relates to the multiple biological functions bioactive com-
pounds can fulfil. They may play a role in cellular communica-
tion, signalling and in the defence of predators and pathogens 
and even may contribute in shaping the structure of marine mi-
crobial communities. 
The scientific work of KiWiZ aims to enlarge our knowledge on 
the biology of natural products by investigation of 
 · the diversity and potential of new marine natural products 
and their producers
 · the role of bioactive compounds in marine microbial inter-
actions
 · the genetics and regulation of biosynthesis of marine bioac-
tive compounds
The second major aspect related to marine natural products 
deals with the potential use of bioactive compounds in phar-
maceutical applications, for crop protection, cosmetics and as 
food additives. This is also the most important aspect of re-
search in KiWiZ. Marine biological resources provided by the 
tremendous biological diversity of marine organisms offer a 
great potential for human uses, in particular bioactive com-
pounds produced by the mostly untapped microbial resources 
(Fig. 2). 
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The exploration of marine microbial resources, the development 
of methods for their biotechnological production with mini-
mised risks for nature and man as well as their sustainable use 
is included in our research strategy by:
 · the analysis of the genetics of marine bioactive compound 
biosynthesis and their application to improve substance 
spectra produced and production rates
 · the analysis and evaluation of the biological activities of 
natural products as well as the development of new bioas-
say systems
 · the development of biotechnological processes for the pro-
duction of bioactive compounds
The performance of these research topics necessitates exper-
tise in bacterial and fungal systematics, in natural product 
chemistry and structure analysis, in bacterial and fungal genet-
ics and physiology, in pharmaceutical targets, in fermentation 
technology and process development. In addition basic, support 
is required to maintain microbial culture collections and chemi-
cal substance library.
KiWiZ as a Thriving Force for Networking and Promo-
tion of Marine Biotechnology
The KiWiZ is engaged in partnerships with national and interna-
tional academic research facilities and commercial enterprises 
to promote natural products to the market for pharmacy, cos-
metics, plant protection and food development. The KiWiZ of-
fers the broad spectrum of available methods including bioas-
says, chemical structure analysis, identification of microorgan-
isms and fermentation to academia and industry in the frame-
work of cooperation projects.
Figure 2: Exampl  of new bioactive compounds from the 
p re c pound substance library of the KiWiZ (Schnee-
mann et al., 2010. J. Nat. Prod. 73:1309–1312; Gärtner et 
al., 2011. Mar. Drugs 9:98–108)
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Most people know that algae grows in oceans, seas and also 
lakes. There are more than 30,000 species of algae which have 
been around for billions of years. Algae represent two thirds of 
the earth’s biomass. Spirulina is a blue-green microalgae natu-
rally thriving in alkaline lakes. It is the most concentrated and 
nutritious whole food known to science.
Spirulina has no nucleus and its cell walls are soft and easily di-
gestable, unlike those of other plants that contain hard cellu-
lose, making it difficult to digest and utilise all their nutitional 
values. A rich nutritional content and a good balance of all nu-
trients make it a perfect source for human food, health as well 
as animal nutrition.
Benefits of using Spirulina
Several hundred scientific studies and clinical trials indicate 
health benefits associated with the use of Spirulina. Spirulina is 
the perfect multinutrient food for people of all ages and life-
styles who want a whole food source of vitamins and other nu-
trients. 
There are many benefits of using Spirulina:
 · Spirulina thrives in alkaline lakes where it is difficult or im-
possible for other microorganisms to survive and can be 
cultivated on poor or deserted lands not suitable for agri-
culture;
 · algae can double its biomass every 2 to 5 days;
 · productivity breakthrough yields over 20 times more pro-
tein than soybeans on the same land area, 40 times more 
than corn and 400 times more than beef;
 · Spirulina protein uses 1/3 the water as soy, 1/5 as corn, and 
only 1/50 the water needed for beef protein.
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Spila Spirulina microalgae applications for human food,  
health and animal feed
Vytas Rimkus | SPILA, UAB, Lithuania
Spirulina is not only good for people, but animals and plants 
thrive on it, too. Many scientific trials – including some conduct-
ed by our company together with partner scientific institutions 
– indicate that Spirulina can be economically efficient and viable 
in animal nutrition and health applications.
When given Spirulina, old cats and dogs with dull, thinning coats 
have been seen to develop thick, lustrous coats; and pets with 
stiff joints appear to improve considerably, becoming supple 
and active again.
Veterinarians prescribe Spirulina to aid recovery, increase stam-
ina, relieve stiffness, and also for show animals for general ton-
ing, as these animals need to look their best.
Prize winning koi carp are fed Spirulina to enhance their color 
and health. Bird breeders add Spirulina to feed to enhance 
plumage color and luster.
Spirulina is used extensively by aquaculture companies to im-
prove the growth rates, increase disease resistance, improve 
survival rates, reduce medication requirements and improve 
quality and coloration of various fish and shellfish.
Feed additive for diary cows
SPILA, UAB applied scientific work carried out by a number of 
international scientists in the field of human nutrition and ani-
mal productivity and economical efficiency. Areas of trials were 
Spirulina for diary cows, use for poultry, pig, carp fish and bees.
Hence we created SPILAMIX, a feed additive for diary cows.
SPILAMIX is a unique feed additive for dairy cows with a special 
component Spirulina that improves the functions of the animal’s 
organism and stimulates its productivity. 
Minimum advantage  
(milk procurement price 0.2 EUR / l, yield increase 3.9 l / cow) 
Number of cows 10 50 100 200 500
1 month 114 570 1,140 2,280 5,700
2 months 228 1,140 2,280 4,560 11,400
3 months 342 1,710 3,420 6,840 17,100
6 months 692 3,458 8,372 17,472 34,350
12 months 1,387 6,935 13,870 27,740 69,350
The minimum and maximum economic SPILAMIX advantage in the dairy cows’ holdings (EUR),  
after product’s cost deduction
Maximum advantage  
(milk procurement price 0.35 EUR / l, yield increase 6.5 l / cow)
Number of cows 10 50 100 200 500
1 month 563 2,813 5,625 11,250 28,125
2 months 1,125 5,625 11,250 22,500 56,250
3 months 1,688 8,438 16,875 33,750 84,375
6 months 3,413 17,063 34,125 68,250 170,625
12 months 6,844 34,219 68,438 136,875 342,188
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SPILAMIX has many features and benefits: 
 · promotes milk yield increases (up to 6.5 l of milk / cow / day); 
 · has a positive effect on milk quality, reduces the number of 
somatic cells up to 26 %; improves the animal’s digestive 
and metabolic processes (up to 5.2 %) and helps assimilate 
some trace elements; 
 · strengthens resistance to diseases (e.g. mastitis); 
 · increases the quantity of erythrocytes (up to 19.3 % 10 12 / l), 
hemoglobin (up to 20.3 % g / l) and hematocrit (62.4 %) in 
the blood, thus reducing the number of leucocytes (up to 
39.3 %);
 · is a high quality product that is free of harmful chemicals 
and side effects. 
The use of unprocessed food rich in natural vitamins has be-
come a trend, as its importance in responce to obesity and dif-
ferent widespread lifestyle diseases (cardiovascular for instance) 
has been understood. 
Understanding this, we created a natural preservation and di-
gestion enchancement Spirulina based product on maximum 
nutrient preservation and without termal preservation thus 
The Lithuanian company SPILA  
uses microalgae applications for human 
food, health and animal feed products.
suitable for vegetarians and everyone from children to elderly 
senior. As it represented unique combinations which were not 
used before it was internationally patented. It proved to be suc-
cessful for its health benefits as well as for its taste which made 
it a part of functional food.
For animal nutrition, our task was to increase benefits for the 
use of natural Spirulina additive versus synthetic or chemical 
animal productivity enhancer. We achieved a significant in-
crease in milking cows’ milk yield and other benefits resulting in 
50 %–400 % net return per day investment on our new SPILAMIX 
product. This is hard to match analogue in this industry.
Outlook
As Spirulina represents hundreds of different forms of nutrients 
and a whole system of interaction, it is a great object for further 
studies for exploring its further benefits for human and animal 
and to enhance its further utilization in many applications also 
as a source of vital elements. 
International co-operation in patent sharing and further prod-
uct development is a main business objective for our company.
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Blue Biotechnology Research Centres in Poland
Alicja Kosakowska & Adam Żak | Institute of Oceanology, Polish Academy of Sciences, Poland
Blue Biotechnology is a dynamically developing branch of sci-
ence. Application of molecular biology methods to marine and 
fresh-water organisms is a worldwide trend which could lead to 
new important discoveries. This modern approach brings many 
opportunities along with possible practical applications and 
benefits for human medicine, pharmacy and industry. The main 
goal of this article is to introduce and describe some of the sci-
entific institutions in Poland that are involved in blue biotech-
nology – taking into account both research projects and future 
perspectives.
Screening for biologically active compounds in marine 
environment
The work at Laboratory of Biochemical Ecology of Microorgan-
isms of the University of Gdańsk’s Institute of Oceanography 
is focused at three strictly interwoven activities: 
 · isolation, cultivation and biomass production of cyanobac-
teria and microalgae, 
 · screening of extracts for biological activity,
 · and activity guided fractionation, isolation and identifica-
tion of bioactive compounds. 
The biological material for the studies is isolated from marine, 
brackish and freshwater environments. In the culture collection, 
more than 150 microorganisms are maintained under conditions 
optimal for growth and metabolites production. Biological activ-
ity of crude extracts, fractions and isolated compounds is ana-
lyzed using an array of biological and biochemical assays. The 
aim of the work is to estimate the potential application of natu-
ral compounds as pharmaceuticals e.g. of antimicrobial, antico-
agulant and cytotoxic activities. Additionally, growth regulating 
activity (herbicidal and algicidal) of the compounds is tested. 
Characterization of chemical structure of natural products is 
based on LC-MS/MS analysis. Mass spectrometry is also used to 
determine metabolic diversity within cyanobacterial genera and 
species. At the moment, the work on marine biotechnology in 
the laboratory is conducted within one European project (FP7 
project MAREX, see p. 13–14) and one national project.
Detection of mutagenic pollution of marine environ-
ment by using genetically modified marine bacteria
Mutagenic pollution of the environment is a global and impor-
tant problem which also occurs in the marine environment. Al-
though many mutagenicity assays have been developed, there 
are specific problems with testing marine water and sediments 
Blue Biotechnology is a dynamically 
developing branch of science in Polish 
research institutions.
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More information & contacts
Laboratory of Biochemical Ecology of Microorganisms, Faculty of Oceanography and Geography, University of Gdańsk 
Prof. Hanna Mazur-Marzec, head of the laboratory 
www.ocean.ug.edu.pl
Department of Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk & Medical University of Gdansk 
Prof. Ewa Łojkowska, head of the laboratory; Dr Krzysztof Waleron 
www.biotech.ug.edu.pl
Department of Molecular Biology, Faculty of Biology, University of Gdańsk 
Prof. Grzegorz Węgrzyn, head of the department 
www.biology.ug.edu.pl
Marine Biochemistry Laboratory, Marine Chemistry and Biochemistry Department, Institute of Oceanology Polish Academy 
of Sciences 
Prof. Alicja Kosakowska, head of the department and laboratory 
www.iopan.gda.pl
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for mutagenic contamination. One of them is the fact that most 
genetically modified strains used in commonly available micro-
biological mutagenicity assays, like Escherichia coli or Salmo-
nella, survive relatively poorly in marine waters, especially those 
of higher salinity. At the Department of Molecular Biology of 
the University of Gdańsk, two alternative assays have been de-
veloped, in which bacteria occurring naturally in marine habitats 
are employed.
The first assay is similar to the Ames test. However, a set of ge-
netically modified, neomycin-sensitive Vibrio harveyi strains is 
used. Mutants resistant to this antibiotic can be easily isolated 
and the frequency of the appearance of such mutants increases 
in the presence of mutagens. To enhance sensitivity of the assay, 
a transposon mutant, very sensitive to mutagenic factors, was 
isolated. The second modification was the introduction of a 
plasmid bearing mucA and mucB genes, coding for proteins in-
volved in an error-prone DNA repair. The assay consists of de-
tection of neomycin-resistant mutants on plates either contain-
ing a mutagen in the solid medium or after incubation of bacte-
rial cultures in a liquid medium, in the presence of tested com-
pounds or environmental samples. Neomycin is an aminoglyco-
side antibiotic that interferes with decoding at the ribosomal A 
site during translation. Resistance to this antibiotic occurs as a 
result of various rRNA modifications in the decoding site. There-
fore, a large spectrum of mutagenic agents, causing different 
types of mutations, may lead to the appearance of neomycin-
resistant mutants, which can be detected. 
The second assay is based on the use of the V. harveyi mutant in 
the luxE gene. This mutant is dim, but upon contact with muta-
gens, fully luminescent revertants or pseudorevertants appear, 
thus luminescence of a bacterial culture became significantly 
increased. It was demonstrated that this increase in lumines-
cence is effective and easily measurable after just a few (2–4) 
hours of treatment with various mutagenic agents, revealing a 
dose-response correlation. Although this assays resembles pre-
viously described and commercialized Mutatox, its advantage is 
a short time of the analysis (a few hours in this assay, relative to 
24 hours in Mutatox). Usefulness of the V. harveyi luminescence 
mutagenicity assay in testing environmental samples has been 
demonstrated for different materials (marine water, sediments, 
marine plant and animal tissues) alone, as well as in combination 
with some other methods. 
Bioactive compounds from Baltic bacteria, cyanobac-
teria and microalgae
The Marine Biochemistry Laboratory is a part of the Marine 
Chemistry and Biochemistry Department at the Institute of 
Oceanology of the Polish Academy of Sciences. Strategic Direc-
tions of the institute’s research are: 
 · role of the oceans in climate change and its effects for the 
European Seas,
 · natural and antropogenic variability  of the Baltic Sea envi-
ronment,
 · contemporary changes of the coastal ecosystems in the 
shelf seas; 
 · genetic and physiological mechanisms of functioning ma-
rine organisms, principles of marine biotechnology. 
The research conducted in Biochemistry Laboratory concen-
trate on the following major topics: 
 · factors influencing transport of metal ions through cell 
membranes and distribution within cells (at present iron),
 · development and maintance of an algal culture collection 
including axenic cultures isolated from the Baltic Sea,
 · short and long term trends in phytoplankton of the Baltic 
Sea; pigments of phytoplankton as ecophysiology and 
chemotaxonomy indicators,
 · isolation and characterization of proteins and siderophore-
like substances (natural iron chelators),
 · allelopathic interactions between phytoplankton species 
and secondary metabolites with biological activity pro-
duced by cyanobacteria and microalgae. 
The studies about secondary metabolites with allelopathic ac-
tivity are important because of their possible influence on 
aquatic ecosystems and potential practical application in phar-
macy, medicine, food science and other branches of industry. 
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Blue Biotechnology –  
Science meets Industry
Blue Biotechnology encompasses the applications of biotechnology tools on ma-
rine resources. With its horizontal scope, Blue Biotechnology covers very differ-
ent applications, for all of which the marine environment is providing the re-
sources. At the SUBMARINER Blue Biotechnology Cooperation Event the focus 
was on four different fields of applications: Genetics, Food, Cosmetics and Phar-
maceuticals. Products developed in these areas have successfully entered the 
market during the last years. One example is the nucleosid Vidarabine (Ara-A) 
which was originally discovered in a marine sponge and serves as an antiviral 
drug for the treatment of herpes simplex infections. For the food sector, one 
important product is the polysaccharide alginate from a brown algae used e.g. 
as thickening agent. Also in the field of cosmetics, “blue” products are used. The 
beta-carotene produced by different microalgae function as an antioxidant coun-
teracting premature ageing of the skin. Finally genetic tools help to investigate 
and understand marine organisms, which create the basis to find e.g. new en-
zymes or substances also from uncultivable organisms. 
Given that Blue Biotechnology is a relatively young discipline with an enormous 
development potential, it is obvious that a lot of Research & Development work 
still needs to be done. The broad variety of presentations given in the “Science 
meets Industry” session demonstrated that this is indeed happening in all these 
fields of application. Different speakers from all over Europe presented topics 
ranging from knowledge capture mechanisms to cultivation of fish cells or suc-
cessful examples within the pharmaceutical industry. Business companies, re-
search institutions as well as regional and trans-European projects were intro-
duced. 
Presentations dealing with functional genomics, the production of omega-3 fat-
ty acids and natural product discovery showed that the Baltic Sea Region seeks 
to keep pace with the rest of Europe. As a showcase of an already successfully 
operating commercial application from the Baltic Sea Region, a company produc-
ing organic cosmetics in Kiel shared its experience with the participants. 
The “Science meets Industry” session provided a fruitful basis for active net-
working and discussions on prospective collaboration, which will be needed to 
develop the future of Blue Biotechnology in the Baltic Sea Region.
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Biotechnological advances in discovery and biosynthesis of  
bioactive secondary metabolites in marine microalgae
Allan D. Cembella | Alfred Wegener Institute for Polar and Marine Research, Bremerhaven, Germany
Eukaryotic microalgae have been extensively studied for bio-
technological applications but the pharmaceutical potential of 
bioactive compounds of marine species has scarcely been ex-
plored. This is in spite of the fact that >120 species of marine 
eukaryotic microalgae are known to produce bioactive metabo-
lites. These allelochemical interactions thus provide a plausible 
discovery and screening approach for novel bioactive metabo-
lites, including insights into pharmacological mode of action.
The Chemical Ecology Strategy 
Many microalgae produce potent toxins or other bioactive al-
lelochemical substance with detectable and often quantifiable 
effects on other components of marine ecosystems, such as 
grazers or competitors. Although the mode of action and func-
tional role of these compounds remains poorly understood, bi-
oeffects-based screening can be an efficient way to enhance the 
probability of discovery of novel bioactive metabolites from 
selected target species. The chemical ecology strategy begins 
with observations of chemically mediated species interactions 
in natural marine environments or in scaled-down systems (mi-
crocosms and mesocosms). This chemical ecology guided ap-
proach is a more focused alternative to blind screening for bio-
activity from a bewildering array of potential candidate species. 
Culture and Harvest Opportunities
Marine microalgae are attractive candidates for biotechnologi-
cal exploitation because they are usually amenable to isolation 
and scale-up for mass culture and can also be harvested direct-
ly from marine environments for optimal yield of bioactives. Key 
microalgae may form dense cellular aggregations or “blooms” 
within the water column or at the ocean surface, which can of-
ten cause water discolouration (red tide). In the case of toxic or 
noxious species, such blooms can lead to serious negative eco-
logical and human health consequences. In the search for novel 
bioactive substances, these dense Harmful Algal Blooms can 
often be harvested from virtually monospecific layers by high 
volume pumping and filtration, e.g. through plankton nets, to 
yield sufficient biomass for extraction and purification of these 
compounds.
Most toxigenic microalgae are primarily phototrophic and there-
fore can be mass-cultivated successfully for biotechnological 
purposes in a variety of photobioreactors, ranging from simple 
batch-culture systems, such as glass or plastic carboys, aquacul-
ture cylinders or suspended plastic bags, to more sophisticated 
continuous-flow chemostats and turbidostats with highly regu-
lated environmental parameters and automated harvesting in 
continuous or semi-continuous mode.     
Molecular Diversity of Bioactive Compounds 
The known bioactive compounds of eukaryotic marine microal-
gae comprise a wide diversity of metabolite groups, from linear 
and polycyclic ethers (e.g., brevetoxins) to tetrahydropurine al-
kaloids (e.g., saxitoxin) and secondary amino acids (e.g., domoic 
acid). Marine flagellates, and in particular the free-living dino-
flagellates, account for >80% of the known bioactive metabo-
lites belonging the polyether class and presumably derived via 
polyketide pathways. With few exceptions, these compounds 
tend to be constitutively produced (when present) within a mi-
croalgal strain – they are not classic inducible stress metabolites 
– but their distribution is typically inconsistent within a genus 
and even among populations or strains within a species. Never-
theless, most strains produce a suite of related compounds from 
a given structural group, rather than a single analogue, and the 
composition appears to be genetically fixed, but the quantity 
per cell may vary widely depending upon growth stage and en-
vironmental conditions. These compounds are usually classified 
as “toxins” because of their high potency to higher vertebrates, 
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particularly mammals and birds, although the ecological and 
evolutionary role (e.g., as chemical defence agents) has not 
been clearly demonstrated. Particularly important from the 
pharmaceutical perspective is the fact that many of these toxic 
compounds act in mammalian systems as ion-channel effectors 
or as enzyme inhibitors, e.g. of protein phosphatases. Such me-
tabolites therefore warrant further investigation regarding their 
potential as analgesics, tumour-promotion/inhibition agents 
and cell cycle regulators.  
In addition to the known toxins of algal origin, known as phyco-
toxins, marine microalgae produce other allelochemicals with 
the capacity to affect species interactions by causing immobili-
zation, loss of membrane integrity and/or cell lysis. These allelo-
Liquid chromatography 
– tandem mass spec-
trometry
Roche 454 pyrosequencing of DNA 
amplicons 
Cell isolation, cloning, identification 
and culture
Shipboard bioprocessing and search for marine 
bioactives from plankton
chemical are structurally distinct from the phycotoxins and can 
comprise larger molecules or macromolecular complexes; the 
molecular targets are unknown but these compounds may also 
provide a fruitful inquiry into bioactive compounds of pharma-
ceutical interest.   
Ecogenomics and Functional Genomics Approaches to 
Biosynthesis
The genomic revolution and post-genomic advances in under-
standing structural and functional gene relationships within and 
among microalgal taxa have already yielded profound insights 
into gene expression and biosynthesis of bioactive metabolites. 
Certain toxic metabolites (e.g. saxitoxin analogues) produced by 
marine dinoflagellates are shared with cyanobacteria and simi-
lar non-ribosomal peptide synthases (NRPS) and polyketide syn-
thase (PKS) genes have been identified. The relative simplicity of 
the cyanobacterial genome can thus provide model systems for 
genomic studies of biosynthetic genes from much more complex 
marine dinoflagellate genomes. An effective strategy for discov-
ery and screening for bioactives from marine microalgae inte-
grates classical natural products chemistry (LC-MS/MS, NMR) 
with genomic and gene expression aspects. Taxonomic gene 
probes and gene expression platforms have been developed for 
several groups of eukaryotic microalgae and associated bioac-
tive gene pathways. Application of high-throughput (e.g., Next-
generation 454)-sequencing, DNA microarrays, and real-time 
quantitative polymerase chain reaction (qPCR) technology to 
microalgae capable of producing bioactive compounds provides 
an effective screening approach to discovery of novel taxa and 
genetic regulation of bioactive compounds in both laboratory 
cultures and complex field assemblages.  
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Knowledge Capture Mechanisms (KCM) are very similar to “Al-
losteric reaction” involving different parameters, control and 
feedback control. Analysis of KCM, at the core of technology 
transfer, contributes to a better understanding of interactions 
between university and industry, technology and knowledge. 
References:
Arnaud-Haond S, Arrieta JM, Duarte CM (2011) Marine Biodiversity and Gene Patents. Science 331: 1521–1522.
Arrieta JM, Arnaud-Haond S, Duarte CM (2010) What lies underneath: conserving the oceans’ genetic resources. Proc Natl Acad Sci 
U S A 107: 18318–18324.
Country
Marine organism 
patent claims
USA 199
Germany 149
Japan 128
France 34
United Kingdom 33
Denmark 24
Belgium 17
Netherlands 13
Switzerland 11
Norway 9
Data from Arnaud-Haond et al (2011).
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The present communication is focused on KCM involving Marine 
Genetic Resources and results obtained by Sophie Arnaud-
Haond et al. It will present a research project and preliminary 
results describing some examples of knowledge transfer path-
ways.
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Database of patents related  
to sequences of marine origin
Origin of patents claims traced using Patentscope 
(World Intellectual Property Office database)
Patents Screening
©
 R
o
b
er
t 
M
ül
le
r 
 /
 p
ix
el
io
.d
e
BASF scientific collaborations developed by researchers 
mentioned as inventors in BASF marine biotech patents
Based on Arnaud-Haond et al (2011).
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Marine functional genomics
Antje Gardebrecht | Ernst-Moritz-Arndt University & Institute of Marine Biotechnology, Germany
Facing the fact that to date most microorganisms remain uncul-
tured, deep metagenome sequencing is indispensable to get an 
impression of microbial diversity and physiological potential in 
a natural habitat. Depending on large specific genome data sets, 
functional approaches such as metaproteomics have been ap-
plied to characterize the dynamic range of in situ expressed 
genes. Starting with a simple microbial assemblage as the sym-
biosis of deep-sea tubeworms and sulfide-oxidizing bacteria, we 
targeted on whole proteomes to resolve functional variations 
between monospecific bacteria residing in two different hosts. 
Challenged by rapid advances in MS/MS-based technologies, we 
furthermore made an attempt to investigate complex microbial 
communities in marine surface waters. Functional genomics al-
lowed to directly link bacteria with metabolic and biogeochem-
ical processes in the North Sea by indification of proteomic bio-
markers. Future analyses of model organisms grown with habi-
tat-specific substrates or being exposed to different stress- and 
limitation factors should give a more detailed picture of key 
proteins in marine systems. In this context, several visualization 
concepts are used to compare expression patterns of such indi-
vidual marker genes under defined environmental conditions. 
Novel identified proteins of unknown function are finally char-
acterized and exploited in respect to new biotechnological ap-
plications.
Biotechnological potential of functional genomics
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Fungi associated to Mediterranean seagrasses and algae: diversity, 
ecological role and potential exploitation
Giovanna Cristina Varese, L. Panno & G. Gnavi | University of Turin, Italy 
A. Kramer & A. Labes | Kieler Wirkstoff-Zentrum am GEOMAR, Germany
Marine environments host a huge biodiversity of microorgan-
isms and a big part of them is made up by fungi that show a high 
biodiversity, a specific habitat composition and seem to be very 
important from both an ecological and biotechnological point of 
view.
The basic knowledge on distribution and ecological role of ma-
rine fungi is still scarce. Marine fungi encompass a wide range of 
saprotrophs, parasites, symbionts, endophytes and epiphytes. 
They can be found in every kind of marine habitats including 
marine microbial communities, marine plants (i.e. algae, sea-
grasses, driftwood), marine invertebrates (sponges, coral, ascid-
ians, bivalves, crustaceans, etc), vertebrates (mainly fishes) and 
inorganic matter1. Recently it has been estimated that marine 
fungi should excess 10,000 species/phylotypes and that many 
poorly investigated sources of marine fungi still exist i.e. algicol-
ous fungi2. 
Moreover marine fungi are a prolific source of new chemical 
diversity and so far have provided many extremozymes and 
more than 1,000 new natural products. Many of these com-
pounds are structurally unique and possess interesting biologi-
cal and pharmacological properties. Among them polyketides 
play a dominant role, and if prenylated polyketides and nitro-
gen-containing polyketids are taken into account, their total 
share will exceed 50 % of all new natural products from marine 
fungi3. However the ecological role of these natural compounds 
is still to be investigated. These metabolites have specific func-
tions in the interrelations between fungi and other organisms. 
They are considered to play an important role in shaping the 
community structures and in mediating interactions among mi-
croorganisms and between microorganisms and their hosts4. 
The aim of this study was to isolate and identify fungi associated 
with the seagrass Posidonia oceanica and to compare it with the 
ones of the green alga Flabellia petiolata and the brown alga 
Padina pavonica which grow in the same phytocenosis. Moreo-
ver about 200 isolated fungi have been screened for the produc-
tion of enzymes and secondary metabolites of pharmaceutical 
interest.
Samples were collected in two sites located in the northern and 
southern part of the Elba island (Italy) at two different bathym-
etries. Plants and algae were serially washed with sterile seawa-
ter, homogenized, diluted and plated on different oligotrophic 
media. Plates were incubated at two different temperatures 
(15 ° C and 25 ° C) and check daily for isolation of colonies that 
have been identified by morphological and molecular tools. 
Despite the two algae are very different from a morphological 
and ecological point of view the total fungal load was very simi-
lar in all the sites. However from a qualitative point of view the 
two mycofloras are completely different.
As regard Posidonia oceanica the four districts (leaves, rhi-
zomes, roots and fluctuating leaves) were separately analyzed 
and displayed great differences in load and mycoflora composi-
tion. Most of fungi were selectively associated with a district 
and only two species were present in all districts. Rhizomes dis-
play the highest load whereas roots and leaves the lowest one.
In accordance with literature, most of the isolated species be-
long to Ascomycota and represent saprotrophic species. Note-
worthy from an ecological point of view the finding of several 
species that in terrestrial habitats usually establish pathosistic 
geneTiCs | science meets industry
Figure 1: Posidonia oceanica (left); Flabellia petiolata (top 
right); c) Padina pavonica (bottom right)
Figure 2: Conidia of Alternaria alternata isolated from 
Posidonia oceanica (left); Cleistotecia of Emericellopsis 
minima isolated from Flabellia petiolata (right).
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Knowledge transfer from environmental genomic science  
to marine biotechnology – big data, big challenges
Johanna B. Wesnigk | EMPA Bremen, Germany
Genomic sequence data are increasing exponentially, also for 
marine organisms and metagenomic data sets. These include 
information for novel functions and promising variety of known 
and utilised enzymes. While costs for the sequencing are de-
creasing, it still constitutes a major effort to obtain and maintain 
samples. Therefore cooperation between science and industry 
is necessary.
Several EU-funded projects address how to facilitate access to 
data, samples and expertise. A dedicated focus on knowledge 
transfer to industry is provided by the CSA project “Marine 
Genomics for Users”, which deals with training, a knowledge 
output database and with establishing direct contacts between 
genomic scientists and marine biotechnologists. Several ele-
ments of this knowledge transfer strategy and a short overview 
on related projects and their outputs are given in the following. 
Furthermore, the emerging large collaborative project Micro B3 
“Marine Biodiversity, Bioinformatics and Biotechnology” will be 
presented. It concentrates on integrating genetic and ecological 
information in one open-access system for linking (meta)genom-
ic prediction to ecosystem biology and to biotechnological as-
pects. Related training will focus on bioinformatic needs by 
these two user groups, including also governance and IPR as-
pects.
The ultimate objective is to learn from marine diversity – from 
fishing bio-active molecules to cultivating organisms and maybe 
soon synthesizing genes – to decipher and apply novel functions 
found in the marine environment.
Marine Genomics for Users
A consortium of seven partners was created to enable wise use 
of the Marine Genomics potential for innovative socio-econom-
ic development. Members are CNRS (Station Biologique de Ro-
scoff), France, as coordinator; UCC (Environmental Research 
Institute) and AquaTT, Ireland; UGOT (Sven Lovén Center), Swe-
den; Dr. Johanna B. Wesnigk, EMPA Bremen, Germany; IRTA, 
Spain; CCMAR, Portugal.
One of the work packages (WP4) focuses especially on the trans-
fer of marine genomics knowledge to industry. It is defining ef-
ficient methods to establish contacts and designing products for 
transfer of MG information to target relevant industrial sectors 
for (joint) development of marine genomics applications. 
Means for the transfer of marine genomics knowledge are direct 
contacts, (e.g. via partnering), dedicated MG sessions at indus-
try conventions, focussed industry workshops (WP3), and a MG 
knowledge output database (WP2). Finally uptake of knowledge 
and its further usage will be evaluated, in WP4 especially in the 
light of enhanced planning of future industry-academia collabo-
rations.
Methodology (for more detail see www.MG4U.eu): 
1. Short questionnaires were distributed electronically and 
during partnering meetings to industry contacts at several 
events (BioMarine, Biotechnica) to help define the needs of 
industry sectors, selected from white, green and red bio-
technologies, fisheries and aquaculture. 
2. Relevant events were chosen for promoting Marine Genom-
ics in dedicated sessions, for example BioMarine and Bio-
technica 2011, Achema June 2012 with a focus on the Bio-
Based Economy and BioMarine October 24-25 2012 in Lon-
don, where marine genomics will be featured in two think 
tanks (www.BioMarine.org)
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Figure 1: Overall approach of the MG4U project. The target 
groups are the marine scientific community, biotech industry 
sectors including aquaculture and fisheries, related govern-
ance and other stakeholders.
The aquaculture sector is among the target groups of the 
“Marine Genomics for Users” project
(plant or enthomopatogenic species) or mutualistic symbiosis 
(lichenicolous fungi) with different organisms. Further studies 
will be necessary to understand their role in marine environ-
ments.
As regard the potential biotechnological applications, about 100 
strains mainly isolated from P. oceanica were screened for the 
capability to produce laccases, peroxidases and tannases in ab-
sence/presence of different NaCl concentrations (15 and 30 g/l). 
Most of the strains were able to produce the tested enzymes; 
many of these enzymes are “extremozymes” since they are trig-
gered only by high salts concentrations. These enzymes could be 
new isoforms very useful in various industrial applications. 
Moreover 98 fungal strains isolated from the analyzed seagrass 
and algae were screened for the presence of two types of pol-
yketide synthases genes (PKS) whose presence is considered 
predictive of the capability to produce useful pharmaceutical 
metabolites. The same strains were also used in an antimicro-
bial screening towards algae, fungi and bacteria potentially 
pathogen for human beings and animals.
About half of the fungal strains showed the genes involved in 
the PKS production. Most of fungi positive for PKS genes come 
from the two algae. This intriguing result may find an explana-
tion from the ecological point of view: P. oceanica is a seagrass 
very rich in tannins, molecules which display high antimicrobial 
activity and involved in competitive interactions with other al-
gae (i.e. Caulerpa taxiflora). On the other hand, it is perhaps pos-
sible to assume that the two algae P. pavonica and F. petiolata 
use the fungi associated with them to defend themselves 
against predators and biofouling.
As regard the antimicrobial screening, several strains display re-
markable antimicrobial properties towards bacterial and fungal 
strains while only a few strains showed antialgal activity. 
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Marine Biodiversity, Bioinformatics and  
Biotechnology (MicroB3)
With a budget of 9 Mio Euro for 4 years (2012–2015) Micro B3 
will develop innovative bioinformatics approaches and a legal 
framework to make large-scale data on marine viral, bacteria, 
archaeal and protists genomes and metagenomes accessible for 
marine ecosystems biology and to define new targets for bio-
technological applications. 
Micro B3 will build upon a highly interdisciplinary consortium of 
32 academic and industrial partners, comprising world-leading 
experts in bioinformatics, computer science, biology, ecology, 
oceanography, bio-prospecting and biotechnology, as well as 
legal aspects.
The work package focussing on marine biotechnology will deal 
with the exploration of integrated datasets looking at genes of 
unknown functions, as well as biosynthetic gene clusters in ma-
rine organisms and new genes from metagenomes. Laboratory 
experiments will be used to further confirm functions through 
pre-enrichments, functional screening of large-insert libraries, 
micro-colonies and micro-cultures as well as heterologous ex-
pression and bioassays.
The work package on intellectual property rights will develop 
documents and run workshops concentrating on 
 · Model agreements for pre-competitive access to microbial 
materials and exchange of materials and data within re-
searchers. 
 · IP model agreements for pre-competitive access to large-
scale microbial genomic research databases and 
 · Outreach workshop on topics like IPR, scientific potential, 
biotech options, environmental impact to discuss applica-
tion and protection options with stakeholders from region-
al, national and international policy-making bodies.
Finally the work-package on dissemination, training and out-
reach will address the timely dissemination of relevant informa-
tion via course, workshops and a programme of outreach to an 
interested public. Three expert workshops with industrial sector 
including SMEs as well as stakeholder workshops with policy 
makers & advisors in field of biodiversity protection are planned.
Another aspect of this package is capacity building through 
training of the next generation of scientists. For more detail in-
cluding registration to the workshops and courses, follow our 
tweet and visit the website www.microb3.eu
	  
Figure 2: Map of geographical distribution of the 32 partners of 
Micro B3 large collaborative project
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three pillars biodiversity, bioinformatics and biotechnology
Analysis of cell powder from in vitro cultured fish cells
Marina Gebert | Fraunhofer Research Institution for Marine Biotechnology (EMB), Germany
Seafood is considered to be important for a healthy diet, as it 
contains valuable proteins and high quality fats as related to the 
omega-6 to omega-3 ratio1. Additionally, the food market pro-
vides us with omega-3 enhanced food, in particular with func-
tional food. The sources of highly unsaturated fatty acids are 
exclusively derived from the marine ecosystem. Beside algal 
sources of omega-3 fatty acids, predominantly cold water ma-
rine fish - especially oily species such as tuna, herring, trout or 
salmon - contain large amounts of highly unsaturated omega-3 
fatty acids. The most important highly unsaturated fatty acids 
are eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA). These have been proven to be beneficial for human 
health. 
However, natural fish sources face two major problems: fish 
stocks stagnate or continuously decrease and heavy metals as 
well as lipophilic toxins like PCBs and PAHs tend to accumulate 
in fat tissue of fishes along the food chain. These lipophilic com-
ponents, which are harmful to human health, are extracted 
along with fatty acids and lower their quality. Aquaculture, 
which is the strongest growing agricultural sector since the late 
1970s, is using aquafeed containing fish meal and fish oil. These 
are as well produced from marine resources, thus putting even 
more pressure on the ecosystem ocean. Already in 2006, 56 % 
of fish meal and 87 % of fish oil was exclusively used for aqua-
feed production2. As aquaculture industry continues to grow, the 
exploitation of novel sources for proteins and omega-3 fatty ac-
ids far from marine ecosystems is ever gaining more importance.
We investigated the ability of a highly proliferative in vitro fish 
cell culture from Sturgeon larvae (Acipenser oxyrinchus) estab-
lished in our laboratory3, which can be converted into “fish cell 
meal”, to produce nutraceutical grade omega-3 fatty acids. We 
found that these cells convert short chain polyunsaturated fatty 
acids into long chain highly unsaturated fatty acids during cell 
cultivation. Figure 1 shows the comparison of fatty acid compo-
sitions from the cell culture medium and the in vitro cell culture 
after harvesting and freeze drying. It is obvious that some fatty 
acids, amongst them DHA, are present in the freeze dried cells 
(green bars) which are not supplemented by the cell culture me-
dium (purple bars).
Encouraged by these findings, we tried to optimize the content 
of omega-3 fatty acids in the freeze dried fish cells. An increase 
of the total amount of EPA and DHA could be achieved by the 
addition of α-linolenic acid (ALA) to the cell culture medium and 
the subsequent reduction of cell culture temperature. In Fig-
ure 2 we compare the fish cells shown in figure 1 with the opti-
mized culture (orange bars). The uptake of ALA was enhanced 17 
fold and the content of EPA and DHA increased 17.3 x and 2.5 x, 
respectively.
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Figure 1: Fatty acid composition of freeze dried fish cells (green 
bars) compared with the cell culture medium used during in vitro 
cultivation (purple bars) in percent of total fat.
Figure 2: Fatty acid compositions of freeze dried fish cells. Un-
treated fish cells (green bars) compared with fish cells treated 
with α-linolenic acid (ALA) and subsequent reduction of the cell 
culture temperature (orange bars) in percent total fat.
However, an industrial production is not yet feasible, as in vitro 
culture of large quantities of anchorage dependent cells is cur-
rently cost-intensive. A scale-up of biomass production, as ac-
complished e.g. in bioreactors (Figure 3), faces some important 
challenges: (i) the discovery of appropriate carriers or scaffolds 
for cell growth, (ii) the achievement of high expansion rates for 
cells and (iii) the reduction of costs, manly through mass pro-
duction and enhanced technology. Resolving these problems in 
future years will enable access to fish derived products under 
controlled conditions, without contaminants and with low eco-
logical damage.
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Production of omega-3 fatty acids by Baltic Sea algae
Kristian Spilling, Jukka Seppälä, Niklas Virkkala, Susanna Nenonen, Elina Salo, Katarina Natunen  
& Timo Tamminen | Finnish Environment Institute – SYKE, Finland 
Dagmar Enss & Heiko Rischer | VTT, Technical Research Centre of Finland, Finland
Algae can contain high amounts of essential fatty acids (EFAs) 
that organisms at other trophic levels have limited abilities to 
synthesize. This has lead to a lot of attention to algae as a poten-
tial feed for aquaculture and as raw material for the nutraceuti-
cal industry. 
Omega-3 fatty acids, in particular Eicosapentaenoic acid (EPA) 
and Docosahexaenoic acid (DHA) have known health benefits to 
humans and these fatty acids are produced in various amounts 
by algae. In order to find what algae would be best suitable for 
EPA and DHA production, we screened 20 different algal spe-
cies, belonging to 4 different phyla, for their fatty acid composi-
tion in both exponential and stationary (N-limited) growth 
phase. 
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Figure 1: Percent of EPA and DHA of dry weight of different 
taxa of algae marked with the horizontal bars on top. The sam-
ples were taken from N starved cultures. The vertical arrows 
denote marine species that were cultivated in full salinity water 
(35 PSU), all the other species originated form the Baltic Sea 
and was cultivated at lower salinity (6 PSU).
Diatoms contained the highest EPA concentrations whereas 
dinoflagellates and haptophytes were high in DHA (Fig. 1). Green 
algae and cyanobacteria contained very little of either EPA or 
DHA (with the exception of Dunaliella salina that contained 
some EPA). Generally, both EPA and DHA content increased in 
stationary growth phase. The highest EPA producer was Thalas-
siosira baltica (3.4 % of DW) and most DHA was found in Scripp-
siella hangoei (9.7 % of DW).
In a separate experiment the effect of different nutrient limita-
tion (N and P limitation) was studied in the diatom Phaeodacty-
lum tricornutum and the haptophyte Isochrysis sp. The total lipid 
concentration was highest during N limitation; however, the EPA 
content in P. tricornutum and DHA content in Isochrysis sp. was 
highest during P limitation, 1.7 % EPA and 1.7 % DHA of DW re-
spectively. 
The results suggest that some algae can contain high amounts 
of omega-3 fatty acids (up to 10 % of DW), but the production is 
highly phyla- and species-specific. The main omega-3 fatty acids 
produced was either EPA or DHA, but not at the same time. Dif-
ferent stress situations (e.g. nutrient limitation) increased the 
overall omega-3 concentration, but species specific optimizing 
should be carried out before any production starts.The cultures were grown in 8 L polycarbonate bottles placed in water baths to ensure constant temperature. The culture me-
dium was F/2, prepared from artificial seawater and inorganic 
nutrient stocks. Cultures were grown at 100 µmol photons m-2 
s-1 in a 16 h light, 8 h dark cycle. Cultures were continuously 
aerated with sterile air pumped through a 0.2 µm filter.
Healthy appetite for Algae: Milk products containing algae
Marie Shrestha | ttz Bremerhaven, Food Technology & Bioprocess Engineering, Bremerhaven, Germany
In Asia, algae are well-known food products since decades. In 
Germany food products based on algae are rare1: algae are pri-
marily used as food additives such as gelling agents (alginate, 
agar and carrageen) or in pharmaceutical and cosmetic applica-
tions2. Algae are rich in vitamins, minerals, trace elements and 
fibre and contain low fat. The raising popularity of Asian food 
products in Europe is contributing to increase consumption of 
food products containing algae and at the same time contribute 
to a general improvement in health. In the current study curd 
and cream cheese products were enriched with brown algae for 
people with nutritive deficiencies3.
Germany is a deficient country for iodine intake and supplemen-
tation of iodine therefore needs to take place through enriched 
food products: iodized salt is a well know example. However 
whilst iodine deficiency interferes with the thyroid function, too 
high iodine consumption also has harmful health effects. The 
recommended daily allowance is 0,15 to 0,20 mg iodine per day. 
The maximum daily intake is 0,50 mg . A thorough formulation 
of dairy products with algae was therefore necessary. 
Young Laminaria saccharina were purchased from an aquacul-
ture farm in the North Sea (Sylter Algenfarm GmbH & Co.KG, 
List, Germany) in June and August 2009. The macroalgae were 
dried under mild conditions, homogenized and incorporated in 
dairy recipes to have a positive influence on the taste, texture 
and appearance of the products. The drying process decreased 
the vitamin C and polyphenol content but had no influence on 
the content of iodine. To efficiently reduce the iodine content 
the algae were immersed in boiling water for one minute.
Algae were used both in powder form to imitate the granulation 
of pepper and in flake form to imitate fresh herbs. The sensory 
acceptance threshold was investigated to determine the maxi-
mum quantity of algae that can be added to cream cheese with-
out impacting negatively the sensorial properties of the prod-
uct. The addition of algae did not influence significantly texture, 
particle size and viscosity of the cream cheese recipes. The io-
dine content of the algae-rich cream cheese products was mon-
itored: A maximum of 500 g algae-rich cream cheese can be in-
gested per day without risk for health.
Consumers’ acceptance and willingness to buy were deter-
mined: 60 men and women between 20 and 65 years of age 
rated cream cheese products containing algae in a blind test. 
Three cream cheese recipes were prepared with and without 
algae: salmon/herbs indish spicies and wild garlic. The accept-
ance towards the innovative algaefood products was good.
The optimisation of drying and grinding of young macro algae 
from the North Sea permits the standardised Production of al-
gae-rich dairy products as prevention against nutritional defi-
ciencies and as contribution towards more taste diversity.
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Figure 2: Influence of treatment of algae on the iodine content 
(claimed by the supplier)
Figure 3: Acceptance profile (from 1 very bad to 7 very good)
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From sustainably cultivated seaweed to certified organic cosmetics 
– The brand “Oceanwell” as a success story for a value-added chain 
originating from ecologically farmed marine resources
Inez Linke | oceanBASIS GmbH, Germany
The company oceanBASIS cultivates the sugarkelp Saccharina 
latissima in an integrative sustainable aquaculture facility in the 
Kiel Fjord. The company is specialised in extracting natural sub-
stances from marine organisms and developes natural products 
for health and beauty such as cosmetics. 
Algae farm
Seasonally marine biologists of oceanBASIS cultivate young al-
gae sporophytes on seeding ropes in the laboratory. After about 
8 weeks they are launched in the openwater farm, which is or-
ganic certified according to European organic standards. The 
seedlings grow about half a year in fresh seawater until the be-
come harvested in early summer.
Extract
After harvesting the fresh algae are fermented to an alcoholic 
extract rich in active marine ingredients such as minerals, io-
dine, special algae sugars and polyphenols.
Cosmetics
Based on this unique extract and natural seawater oceanBASIS 
developed the NaTrue certified organic cosmetic brand “Ocean-
well” with 10 products for face and body skin care. Nationally 
Oceanwell is distributed via an online shop, perfumeries, natural 
cosmetics shops, spas and hotels. Export has started recently 
first to China, now to the USA.
Clinical and Dermatest studies revealed that Oceanwell has a 
beneficial skin-compatible effect. Thus it is suitable especially 
for dry and sensitive skin. Moreover, Oceanwell moisturizes, re-
generates, energizes and protects the skin in a natural way.
After 7 years of research oceanBASIS invented a new cosmetic 
ingredient, oceanic collagen, extracted from jellyfish. Studies 
revealed unique high waterbinding capacity. The organically cer-
tified cosmetic ProAge Line “OceanCollagen” was developed 
specially for demanding skin. Dermatest studies showed that 
wrinkles depth is reduced significantly (–25 %) by the OceanCol-
lagen face cream.
  
Oceanwell Basic.Line –
marine and pure
- moisturize
- regenerate
- protect
- revitalize
  
               Face Cream
                    „Most Innovative Natural Product 2012“
OceanCollagen ProAge Line
Sulfated polysaccharides of Delesseria sanguinea  
from the artificial reef Nienhagen
Susanne Alban, Niels Grünewald, Juliane Grimm & Inken Groth | Pharmaceutical Institute, Christian Albrechts 
University of Kiel, Germany
In 2003, a large-scale artificial reef was established in the Baltic 
Sea close to Nienhagen (Germany) in order to increase the local 
fishery resources. In addition to an increase of the fishing value, 
the reef structures turned out to be abundantly colonized by 
algae, predomi-nantly by the perennial red macroalga Delesseria 
sanguinea (Hudson) Lamouroux (D.s.). Compared with D.s. oc-
curring in North Atlantic and North Sea, D.s. from the reef has 
the advantage to be scarcely contaminated with epiphytes. 
Since algae-based products are of growing interest, the sub-
project ‘Evaluation of the economic applicability of the Baltic 
Sea red alga Delesseria sanguinea’ was initiated. 
D.s. turned out to contain substantial amounts of a non-gelling 
sulfated polysaccharides consisting of a homogenous fraction of 
branched sulfated xylogalactans (D.s.-SP) (galactose: xylose 
~5.4)1 (Figure 1). 
D.s.-SP has a pharmacological profile indicating anti-inflamma-
tory and anti-skin aging potencies1, 2. It exhibits inhibitory ef-
fects on extra-cellular matrix degrading enzymes like PMN-
elastase, hyaluronidase, heparanase, collagenase (MMP-1) as 
well as on the alternative and classical complement activation, 
the adhesion of neutrophils and tumor cells to P-selectin and 
the cytokine release from LPS-activated monocytes. Further, 
D.s.-SP is neither cytotoxic nor phototoxic and showed potent 
free radical scavenging activity by inhibiting the genera-tion of 
reactive oxygen species in UV-irradiated human keratinocytes 
(HaCaT). 
Comparison of the activity profiles of D.s.-SP with those of hep-
arin, the prime example of a bioactive sulfated polysaccharide, 
and of PS3, a semisynthetic β-1,3-glucan sulfate with proven in 
vivo anti-inflammatory potency2, 3, revealed the following4: 
1. both D.s.-SP and PS3 have only moderate anticoagulant ac-
tivity and thus a considerably reduced bleeding risk; 
2. most of the other activities of both D.s.-SP and PS3 are con-
siderably stronger; 
3. D.s.-SP and PS3 have a similar, but not identical activity pro-
file (Figure 2). 
Crucial for an economic use is the availability of adequate 
amounts of D.s.-SP with reprodu-cible high quality. For this, al-
most 230 D.s.-SP batches were isolated from 30 D.s. batches 
harvested over the period of 6 years, analyzed and tested. The 
results impressively illustrate that “the process defines the 
product” as known for biological compounds. By evaluating nu-
merous parameters potentially influencing the quality of D.s.-SP 
and successive optimi-zation of the process, the D.s-SP can now 
be isolated in reproducibly high quality by using a specific ex-
traction procedure (Figure 3). This is an important difference of 
the D.s.-SP compared to other algae-derived extracts and com-
pounds (e.g. fucoidans)5. The average yields of D.s.-SP originally 
amounted to 11.9 ± 4.4% in dependence on the harvest time of 
the algae [6] (Figure 4), but could meanwhile be increased to 
about 20 %. By applying the established procedure, a scaling-up 
experiment (100 kg fresh D.s.) led to D.s.-SP of identical quality 
as obtained in our lab.
Acknowledgments: This project is financed by the EU (FIAF/EFF) 
and the LFALF Mecklenburg-Vorpommern.
Compared to red algae from the North 
Atlantic and North Sea, Delesseria 
sanguinea from the Baltic reef  
has the advantage of scarcely  
being contaminated with epiphytes.
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Figure 1
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Traditionally, higher plants and terrestrial microorganisms have 
proven to be the richest sources of natural drugs. However, we 
are living in a planet of oceans. The marine ecosystem covers 
more than 70 % of the Earth’s surface but represents 95 % of the 
biosphere. The first living organisms appeared in the sea more 
than 3,500 million years ago and evolutionary development has 
equipped many marine organisms with the appropriate mecha-
nisms to survive, developing exquisitely complex biological and 
chemical mechanisms for defence, attack, signalization and 
other still unknown purposes. These biological capabilities are 
clearly revealed by their ability to biosynthesize and release po-
tent chemical weapons that are active per se.
Such novel chemical structures often result in new modes of 
action and open up the potential of new ways to treat cancer 
and other diseases. The current scientific, academic and bio-
tech-pharmaceutical industries have recognized this opportu-
nity and thousands of bioactive compounds are being discov-
ered and some of them are being testing in clinical trials, mainly 
in oncology. But the conversion of a bioactive molecule into a 
medicine is a long and risky process. It involves astronomic in-
vestment for developing the identification and validation of new 
targets, drug discovery, medicinal chemistry and drug delivery, 
apart from ensuring the future supply, where chemical synthesis 
and biotechnology are the preferred sources for manufacturing. 
From marine biodiversity to innovative drugs.  
The experience of PharmaMar
Fernando de la Calle | PharmaMar S.A., Spain
This was are the case of the PharmaMar pipeline compounds as 
the anticancer medicine Yondelis® (PharmaMar, Spain) isolated 
from a marine tunicate Ecteinascidia turbinata, that is currently 
manufactured using a hemi-synthetic process or the total syn-
thesis for manufacturing Aplidin®, peptide isolated from the tu-
nicate Aplidium albicans.
Natural collections are typically used only for drug discovery 
purposes, where only small amounts (milligram scale) of the 
pure compound are enough to elucidate the chemical structure 
and the biological activity. 
The marine bioprospection, involving the study of extracts from 
invertebrates, microorganisms and recently, exploring DNA 
from uncultivable organisms, involves large amount of invest-
ment and is a long and risky process with a low chance of finally 
reaching the market. Today, it is essential to innovate efficiently 
for increasing the probability of developing new scaffolds, re-
ducing time and costs. 
The classical view of marine biotechnology has been radically 
changed with the advent of molecular tools, mainly due to in-
novative methods for detecting uncultured microorganisms and 
the massive and efficiency use of DNA sequencing technologies 
and powerful computation features to define interesting gene 
cluster and prediction of core structures formed by them. 
science meets industry | CosMeTiCs PharMaCeUTiCaLs | science meets industry
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Now, the concept of biological diversity is based on an enor-
mous universe of DNA sequences, where the majority of the life 
forms cannot be cultivated in the laboratory. In addition, thou-
sands of whole microbial genomes are being sequenced and a 
large number of silent genes related to secondary metabolisms 
are appearing, potentially responsible of the biosynthesis of 
new chemical scaffolds which could be expressed by heterolous 
expressions in the close future. This is great news for the scien-
tific community (and, of course, for the biotechnology sector). 
It opens up the possibility of analyzing all this genomic content 
as potential genes (mainly Polyketide Syntheses and Non Ribo-
somal Peptide Synthetases) able to produce innovative pharma-
ceutical compounds and enzymes.
As example of the potential of genomic mining are the cases of 
the recently published hypothetical biosynthetic pathway of tra-
bectedin (Yondelis) by pyrosequenciation and informatic anno-
tation of NRPS belonging to associated microbial symbionts in 
the ascidia E.turbinata1 or the description of the complete gene 
The conversion of a bioactive molecule into 
a medicine is a long and risky process 
involving astronomic investments.
cluster PKS/NRPS of didemnins, chemical family of Aplidin, in a 
mega plasmid in a free living alpha proteobacteria2. This family 
class of metabolites had been described only in marine ascidi-
ans. 
Today we are beginning to explore this metagenomic approach. 
Soon, the number of new compounds with applications in hu-
man health is expected to increase dramatically as a result of 
using innovative genetic technology. 
PharmaMar (Zeltia group), a Spanish biotechnology company, 
devoted on the research and development of marine natural 
products for the treatments of human cancers, is developing an 
ambitious drug discovery programme using marine samples.
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Marine microorganisms – a promising source for novel therapeutics
Sabine Mundt, Wolf-Dieter Jülich & Ulrike Lindequist | Institute of Marine Biotechnology e.V. and Institute of 
Pharmacy, Ernst Moritz Arndt University Greifswald, Germany 
Gerold Lukowski | Institute of Marine Biotechnology e.V., Germany
Marine natural products chemistry was born in the 1960s and 
entered adolescence during the 1980s. The number of natural 
products discovered annually increased from less than 100 to a 
level of about 500 products per year in the late 1990s. In 2010 
more than 1,000 new structures with a wide range of bioactivi-
ties have been published. Worldwide marine organisms, espe-
cially more and more microorganisms such as fungi, bacteria 
and cyanobacteria, are recognized as sources for novel natural 
products.1-3
The focus of research in our group is the isolation and charac-
terization of active compounds produced by marine fungi and 
cyanobacteria (see below pictures). Based on a culture collec-
tion of more than 400 strains isolated from different sources 
(Baltic Sea, North Sea, Red Sea, South China Sea, Vietnam and 
South Sulawesi, Indonesia) organisms are cultured in different 
volumes from 100 ml until 50 l (see pictures on right page). Ex-
tracts are prepared from biomass and cultivation medium with 
solvents of different polarity and tested in-vitro for activity 
against Gram-positive and Gram-negative bacteria and patho-
genic fungi, for cytotoxic activity to tumor cells and for activity 
against viruses such as influenza virus and herpes simplex virus. 
Active substances are isolated bioassay-guided by column chro-
matography including HPLC and the structures are elucidated by 
NMR and MS.
Fractionation of the ethyl acetate extract of the cultivation me-
dium of the ascomycetes fungus Corollospora maritima, isolated 
from driftwood collected near Helgoland, resulted in the identi-
fication of the natural phthalide derivative corollosporin A. The 
compound inhibits the growth of Gram-negative and Gram-
positive bacteria.4 Two benzofuranoids, deuteromycol A and B, 
have been isolated from the ethanol extract of the marine-de-
rived strain MF 003 (Deuteromycete), obtained from Red Sea 
mangrove drift wood and seem to be responsible for the activ-
ity of the ethanol extract to different Staphylococcus aureus 
strains including MRSA.5 Fungal strains from Indonesian marine 
habitats were isolated and the ethyl acetate extracts tested for 
antifungal activity to plant pathogenic fungus Cladosporium cu-
cumerinum. From the culture broth of the endophythic Daldania 
eschscholzii strain isolated from red alga Gracilaria sp. SGR-1 the 
lactone heliascolid C was isolated as the active compound with 
specific antifungal effects.6 Six new naphthalenone derivatives, 
Balticols 1–6, from an ascomycetes fungus, isolated from drift-
In 2010, more than 1,000 new  
structures with a wide range of  
bioactivities have been discovered. 
Marine fungus on agar
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wood, collected from the Greifswalder Bodden, displayed in-
hibitory activity against influenza virus A and herpes simplex 
virus.7
From cultivated Vietnamese cyanobacteria belonging to the Ge-
nus Nostoc polyketides with strong cytotoxic activity to tumor 
cell lines and moderate antibacterial effects were isolated. It 
was shown, that the compounds possess stronger cytotoxic ac-
tivity against tumor cells than against non transformed cells.8 A 
Lyngbya strain was identified as the source of antibacterial and 
cytotoxic active cyclic undecapeptides, lyngbyazothrins A–D9. 
The methanol-water extract prepared from the biomass of the 
Anabaena strain Bio 33, obtained from the Baltic Sea near island 
of Ruegen, exhibited specific activity against human pathogenic 
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Figure 1: Influence of Maresome® prepared from biomass of Bio 
33 (N=157), Spirulina and Chlorella (N=14) on colonization of 
MRSA (NES) in cow udder test (direct contamination after treat-
ment with Maresome® ointment)11
Figure 2: Influence of Maresome® prepared from biomass of Bio 
33 (N=54) on colonization of different MRSA strains and Pseu-
domonas aeruginosa in cow udder test (direct contamination 
after treatment with Maresome® ointment) 
*Vancomycin resistant MRSA Mu50
yeasts and fungi, such as Candida albicans, Aspergillus and Mu-
cor sp. Complex cyclic lipopeptides are responsible for antifun-
gal activity; structure elucidation is in progress.
Besides the isolation of pure active compounds we use whole 
biomass of marine microorganisms to prepare microparticles by 
Maresome-technology.10 It could be shown that microparticles 
from the biomass of Bio 33 called Bio33-Maresome® (see pic-
ture on left page) in-vitro inhibit dermal colonization of different 
MRSA strains and even of the VRSA MU50 strain (Fig. 1–2).11 A 
prophylactic skin care with Bio33-Maresome® to prevent noso-
comial infections has been developed. First in-vivo data have 
confirmed the in-vitro effects.
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Cultivation of cyanobacteria Air-lift fermenter for cultivation 
of cyanobacteria 
Fermenter for cultivation 
of marine fungi 
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AAC – Algae Against Cancer:  
Preliminary data of a national research project
Marion Zenthoefer & L. Piker | CRM – Coastal Research & Management, Germany 
M. Peipp, M. Gramatzki, U. Geisen & H. Kalthoff | University Medical Center Schleswig-Holstein (UKSH), Germany 
Y. Weniger & S. Alban | Christian Albrechts University Kiel, Germany 
S. Hennig | Source BioScience Ltd., Germany 
M. Fuhrmann, F. Huber & R. Kirchhöfer | LipoFIT Analytic GmbH, Germany
Based on previous studies, demonstrating significant inhibitory 
effects on proliferation of tumor cells triggered by various ex-
tracts of different macroalgae (Fig. 1), a national research net-
work will now enlighten structure and mechanisms of action of 
potent ingredients of marine algae.
In the project “Algae Against Cancer” (AAC), funded by the Fed-
eral Ministry of Research and Education (BMBF), three private 
and three university partners investigate cellular responses 
Figure 1: Effects of algae extracts (each number is repre-
senting a different extract) on the proliferation of human 
lymphoma cell line Raji. Dark wells: strong proliferation, 
pale yellow: low proliferation.
upon treatment with algae-derived extracts. Possible synergistic 
effects of a combined action of several substances will be ana-
lyzed with innovative methods of genomics and metabolome 
analysis.
Preliminary results from studies with different hematologic and 
solid tumor cell lines are presented showing patterns of inhibi-
tion of cell proliferation (Fig. 2). Some algae extracts inhibit also 
target enzymes like Elastase or Thyrosinkinase species.
Furthermore, first alterations in gene expression profiles have 
been detected and will lead to the selection of target genes as 
objects for a detailed qPCR study. 
Also, metabolic responses have been identified in terms of NMR 
analyses. The differences in the composition of metabolites in 
algae extract-treated and untreated tumor cells (Fig. 3) will re-
sult in a range of model components, which will give insight into 
metabolic changes and, thus, help to identify possible anti-can-
cer mechanisms.
The first results suggest a real chance, i) for specifying substanc-
es that have not yet been described as cancer therapeutics, ii) 
for the identification of structural modifications of already 
known drugs leading to improved anti-tumor activity, and iii) for 
describing previously unknown mechanisms of action of known 
algal ingredients.
Figure 2: Cell viability in terms of a XTT-assay after 
incubation (72 h) of six solid tumor cell lines with an algae 
extract using different concentrations. 
Figure 3: Comparison of the signals from two different NMR 
spectra (from solid tumor cells treated with an algae extract 
vs. not treated).
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Integrated analytical approaches towards  
marine natural products discovery
Thomas Ostenfeld Larsen, Maria Månsson & Kristian Fog Nielsen | Center for Microbial Biotechnology (CMB), 
Technical University of Denmark, Denmark 
Charlotte Held Gotfredsen | Department of Chemistry, Technical University of Denmark, Denmark 
Lone Gram | National Food Institute, Technical University of Denmark, Denmark
Per Juel Hansen | Marine Biological Section, University of Copenhagen, Denmark
Many strategies can be followed in discovering novel drugs from 
microbial sources. We have demonstrated that phenotypic 
based microbial taxonomy can be a successful path to microbial 
drug discovery1. This involves the use of multivariate methods 
for clustering and selection of talented strains for testing in 
various bioassays (e.g. antimicrobial, anticancer). The second 
step in the discovery process is dereplication, where we use 
state-of-the-art high resolution mass spectrometry (<1 ppm 
mass accuracy and accurate isotope pattern) in combination 
with comprehensive compound databases in order to ensure 
not to waste time isolating and elucidating the structures of al-
ready known compounds2. When likely unknown compounds 
have been identified an explorative solid-phase extraction ap-
proach3 is applied for micro-scale fractionation on a set of dif-
ferent types of columns (RP, ion-exchange, size, NP), in order to 
determine more chemical properties of the bioactive(s). This 
further aids selection of a fast optimal purification strategy to-
wards the pure bioactives prior to NMR characterization. 
The presentation illustrated our integrated analytical approach-
es and highlighted some of the results that we have gained in a 
recent larger Danish biodiscovery project focusing on marine 
bacteria4–6, as well as some of our future challenges in determin-
ing the chemistry of microalgae and marine derived fungi.
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Aquapharm – Application of Blue Biotechnology  
for the discovery of novel pharmaceuticals
Andrew Mearns Spragg | Aquapharm Biodiscovery Ltd, European Centre for Marine Biotechnology, United Kingdom
We live on a Blue Planet: more than 70 % of the Earth’s surface 
is covered by oceans. Our economies and our health and wellbe-
ing are critically dependant on the resources and services pro-
vided by the seas and oceans. Aquapharm Biodiscovery Ltd is an 
innovative discovery company pioneering the development of 
new pharmaceuticals and functional ingredients founded on the 
vast, untapped diversity of marine micro-organisms.
Over the past 20 years, the pharmaceutical industry has seen a 
decrease in discovery and success based on computational and 
combinatorial chemistry, and an increase in base costs imposed 
by increasing regulatory requirements and a higher rate of fail-
ures during the development process1. Couple this to the poten-
tial of structural, hence intellectual property overlap between 
libraries of synthetic compounds and the need for low-cost, 
scalable, and chemically unique new scaffolds, the pharmaceuti-
cal industry is starting to re-evaluate the potential of natural 
products to provide the industry with new drug leads.
Modern pharmaceutical drug discovery owes much to natural 
product research as more than 61 % of small molecule chemical 
entity (NCE) drugs marketed between 1981 and 2002 originated 
from natural products.2,3 For antimicrobial and anticancer thera-
pies, the figures are 78 % and 74 % respectively.  The majority of 
these products have been derived from so called ‘secondary 
metabolites’ of terrestrial microorganisms, however the rate of 
new chemistry discovered from land based organisms has 
slowed and there is growing recognition of the potential of the 
marine environment for the provision of new biological and 
chemical diversity.
Marine organisms are highly diverse and represent a unique 
source of genetic information and biochemical complexity, as-
sociated partly with a.) genetic diversity with for example four-
teen endemic (unique) marine phyla compared with just one 
endemic terrestrial phylum, for example, and only perhaps 
240,000 different organisms found so far by the Census of Ma-
rine Life out of an estimated 1.4–1.6 million - and partly with b.) 
ecological diversity - habitats range from beaches and mudflats 
to extreme ocean depths of 11 km, more than hundreds of me-
tres deep in sediments, as well as the water in-between, all with 
enormous physical and chemical variability.4
Marine biodiversity is potentially exploitable in a wide range of 
economically important sectors. Large numbers of marine-ori-
gin molecules with structural novelty are now being described 
on monthly basis, which highlight the significant growth which 
has recently taken place in the screening and exploitation of ma-
rine genetic resources. More than 18,000 natural products and 
4,900 patents have to date been derived from the genes of ma-
rine organisms, and the number of patents is increasing by 12 % 
per annum. In the healthcare area, for example, there continue 
to be unmet needs in managing and treating cancer, chronic in-
flammatory diseases, metabolic dysfunctions and infectious dis-
eases5 . Currently there are around 15 marine natural products 
in various phases of clinical development, mainly in the oncol-
ogy area, with more on the way and several products already on 
the market. 
Examples of marine natural products of pharmaceutical potential
Product Disease 
indication
Compound origin 
(Organism)
Status
Prialt® Neuropathic 
Pain
Conus magus (Mol-
lusc)
Commercial
Yondelis® Cancer Ecteinascidia turbi-
nata (Ascidian)
Commercial
Halaven® Cancer Halichondria okadai 
(Sponge)
Commercial
Salinispora-
mide
Cancer Salinispora tropica 
(actinomycte)
Phase I
Plinabulin Cancer Aspergillus sp. (Fun-
gus)
Phase II
Pelorol Inflammation Dactylospongia ele-
gans (Sponge)
Not Known
To support Aquapharm’s own screening efforts to find novel 
chemistry,  the Company has developed a proprietary drug dis-
covery tool; SeaRch™ ; a novel method of accessing chemistry 
locked away in cryptic biosynthetic pathways within micro-or-
ganisms.
SeaRch™
Due to the fundamental limitations of accessing the full range of 
chemical productivity produced from micro-organisms (marine 
or terrestrial) many of which are present in “cryptic” / or locked 
away biosynthetic pathways, Aquapharm has developed a novel 
approach of modulating the microbial metabolome to unlock 
the bio-synthetic potential of micro-organisms for the discovery 
of new compounds – many of which are capable of modulating 
hard to drug protein: protein drug targets. This is our SeaRch™ 
Figure 1: A marine microbial biofilm exposed to oxidative 
stress conditions (right) vs normal culture conditions (left) 
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platform which leverages IP initially filed in 2007 on techniques 
to achieve the reactivation of cryptic secondary metabolite 
pathways in micro-organisms via epigenetic remodeling in re-
sponse to the induction of oxidative stress6. 
Aquapharm has utilized SeaRch™ to screen 1,100 marine strains 
from its collection of over 9,500 marine isolates, for the discov-
ery of novel antibiotic and anti-inflammatory compounds with 
our partners AMRI based near Seattle.  
Preliminary data has demonstrated that this has been a great 
success and has yielded a substantial number of novel pharma-
cophoric scaffolds, many of which are below 500m/z and fall 
well within the Lipinski rules for drug like chemistry. Further 
screening of some of these novel drug-like compounds against 
a broad range of GPCRs , enzymes & ion channels has discovered 
chemistry that is highly potent and also highly specific against 
interesting and complex drug targets reading onto CNS & oncol-
ogy.
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Figure 2: Example of increased production of secondary 
metabolites by an Aquapharm microbial strain treated by 
SeaRch™ – HPLC profiles of crude extracts produced by AQP 
strain cultured under stressed SeaRch conditions (red) vs. 
non-stressed culture conditions (blue)
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Genome based methods for the exploration of natural products 
from marine fungi for the treatment of cancer
Antje Labes | Kieler Wirkstoff-Zentrum at Helmholtz Center for Ocean Research GEOMAR, Germany
Marine Fungi represent an excellent source for new bioac-
tives1,2. However, understanding the complexicity of a neglected 
group with diverse functions is still far away. Marine fungi are 
not well characterised and underutilised in terms biotechno-
logical application. A comprehensive scientific rationale has to 
be applied (fig. 1).
Beside isolation of new fungal strains from unique marine habi-
tats, the molecular development of effective producer strains is 
in the focus. Genomes of selected candidate strains originating 
from our unique strain collection of marine fungi are character-
ised with respect to secondary metabolite production. This 
knowledge is used to optimise production using molecular 
methods. 
Since in the case of secondary metabolites, genetic potential 
does not mean production, comprehensive approaches are 
needed, combining culture based methods as: targeted isola-
tion, screening of strain libraries, in situ enrichments as well as 
culture independend methods as: specific genetic screening, 
metagenomics, genomics. The KiWiZ holds the EU’s larges cul-
ture collection of marine fungi (>10,000 strains, fig. 2) – molecu-
lar methods can be applied to improve selections of strains for 
screening.
Since in fungi secondary metabolite genes are organized in clus-
ters, the assumption was made that biosynthetical genes are 
markers for the selection of producers of secondary metabo-
lites. Concerning (marine) fungi, a genetic screening for polyke-
tide synthasese (PKS) genes was available but not for non- ribo-
somal peptide synthetase (NRPS) genes3,4. We were able to 
verify PKS genes in marine fungi using the Nicholson system 
(Klotz unpublished). The question was: Are these genes good 
markers? This was only shown for some groups, eg. Penicillium, 
which is not surprising (Kramer, unpublished) – so genomes are 
needed. As first candidate, Scopulariopsis brevicaulis was choos-
en (fig. 3.)
Figure 1: Scientific rationale in order use marine fungi as a 
sustainable source for new bioactives
Marine natural products 
Linking ecology and  
biotechnology
Microbial interaction 
Understanding communi-
cation at the µm-level
Biology of marine fungi 
Understanding the complex-
ity of a neglected group 
with diverse functions
Here, we demonstrate the sustainable exploitation of marine 
natural resources providing appropriate culture conditions for 
the group of marine fungi, thus enabling efficient production of 
marine natural products in the laboratory and also in large scale 
cultures, avoiding harm to the natural environment. In the focus 
are new anti-cancer compounds. 
Figure 2: The Kieler Wirkstoff-Zentrum at GEOMAR holds a cul-
ture collection of appr. 10,000 marine fungi and has access to 
different marine habitats. A particular high percentage of micro-
organisms associated with various macroorganisms (if compared 
to free living microbes in ocean waters) are able to produce sub-
stances interesting for pharmaceutical production. Therefore 
sponges, bryozoa, algae, corals and other marine macrobes 
(small photos) are sampled to gain new strains.
	  
Figure 3: Scopulariopsis brevicaulis from a marine sponge was 
choosen for genome sequencing5
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»Much of nature’s treasure  
trove of small molecules remains to be 
explored, particularly from the marine and  
microbial environments.«6
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Compounds originating from those approaches will be charac-
terised to the stage of in vivo proof of concept ready to enter 
further drug development in order to valorise the results of an 
EU FP 7 project (MARINE FUNGI, 259625). This approach is an 
outcome of the project “MARINE FUNGI” within the KBBE 
framework of EU’s FP7 . We develop a process concept for these 
compounds providing the technological basis for a sustainable 
use of marine microbial products as result of Blue Biotech. 
Therefore, we will explore the potential of marine fungi as excel-
lent sources for useful new natural compounds along the added-
value chain from the marine habitat to the drug candidate and 
process concept.
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Improving the Baltic Sea environment and  
economies: Innovative approaches to the  
sustainable use of marine resources
The Baltic Sea Region faces enormous challenges including new installations, fishery declines, 
excessive nutrient input, the effects of climate change as well as demographic change. But nov-
el technologies and growing knowledge also provide opportunities for new uses of marine eco-
systems, which can be both commercially appealing and environmentally friendly. Through in-
creased understanding and promotion of innovative and sustainable new uses of the Baltic Sea, 
SUBMARINER provides the necessary basis for the region to take a proactive approach towards 
improving the future condition of its marine resources and the economies that depend on them. 
It does so by focusing its efforts along four lines of activity:
 · Production of a compendium: describing current and potential future marine uses by de-
veloping a comprehensive inventory of innovative sustainable uses, assessing their environ-
mental and socioeconomic impacts, estimating the market opportunities and the availabil-
ity of necessary technologies, and describing the gaps and obstacles in the legal framework.
 · Development of a roadmap: recommending necessary policy steps to promote beneficial 
uses and mitigate against negative impacts, including suggested legal changes (e.g. spatial 
plans), environmental regulations and/or economic incentives.
 · Implementation of regional development activities: testing new uses in real conditions, 
conducting feasibility studies for new uses in specific areas, assessing technological and fi-
nancial needs, estimating impacts on environmental and socieconomic conditions, and 
evaluating specific legal constraints.
 · Building a network: creating a selfstanding, independent network for sustainable innovative 
marine uses and stimulating cooperation among relevant players through virtual and real 
networking, information exchange and cooperation events.
www.submariner-project.eu
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